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Abstract 
Women represent a growing proportion of new positive HIV tests in Canada and are 
more likely to experience comorbid depression. This is concerning because comorbid 
depression is associated with suboptimal adherence to highly active antiretroviral therapy 
(HAART) and poor HIV disease outcomes. The purpose of this project is to answer the 
question, "What is the role of the nurse practitioner (NP) in optimizing adherence to HAAR T 
amongst marginalized, HIV -positive women with comorbid depression?" By evaluating 
current literature this project found that social factors such as poverty, homelessness, food 
insecurity, post-traumatic stress disorder, stigmatization, gender or racial discrimination and 
injection drug use are risk factors for both comorbid depression and HAART non-adherence. 
Effective treatments for depression include cognitive behavioral therapy and 
pharmacological intervention with antidepressants. The role of the NP was inferred by 
extrapolating the findings from this literature search with the competencies required ofNP 
practice. NPs have the skills, education and legislated authority to provide collaborative care 
that addresses the underlying social factors that contribute to comorbid depression and 
HAART non-adherence. These findings are limited by the scarcity of research conducted 
with HIV -positive female participants, that investigates NP practice or interventions to 
address underlying social factors . 
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CHAPTER ONE 
Introduction 
Throughout the Master of Science in Nursing program, I have been exposed to 
critical social justice theory and primary health care (PHC) principles that have sparked my 
interest in working with marginalized populations. Marginalization refers to social 
conditions or processes that make or treat, certain individuals or groups, as 
insignificant, and ultimately results in "a disproportionate burden of ill health and 
social suffering" (Barber, Fitzgerald, Howell, & Pontisso, 2006; Browne, et al., 2012, 
p.2). Marginalization can prevent an individual or group from achieving the beneficial 
determinants of health. 
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The social determinants of health refer to social, political and economic conditions 
that shape the environment within which people live. These factors are negatively affected by 
the inequitable distribution of wealth, power or resources. Many health disparities, such as 
infant mortality rates, incidence of childhood obesity or life expectancy at birth, are 
attributable to the social determinants ofhealth. Key social determinants of health include 
education, gender, income, race/ethnicity, food security, housing, early childhood 
development, social exclusion, and health services (Mikkonen & Raphael, 201 0; WHO, 
2013a). The social determinants ofhealth draw attention to the idea that health and health 
status are influenced more so by the social conditions imposed on individuals or groups, than 
by individual lifestyle or personal choice. 
Gender is recognized as a key determinant of women's health status (WHO, 
2013b). The same social, sexual, and cultural factors that define gender and its 
associated roles, responsibilities, status and power, also directly interact with the other 
determinants of health. This results in a compounding of gender based inequities that 
decrease women's ability to achieve optimal health and decrease resiliency to diseases 
such as human immunodeficiency virus (PHAC, 2012b). For example, a homeless, 
single-mother may feel forced to enter into an abusive relationship in order to obtain 
housing and food for her children. Because she is reliant on and fearful of her partner, 
she may not be able to negotiate safer sexual practices and she becomes infected with 
HIV. 
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In the three decades since the human immunodeficiency virus (HIV) was identified as 
the causative agent behind acquired immunodeficiency syndrome (AIDS), HIV has changed 
from a terminal diagnosis, to a manageable, long-term chronic trajectory. While there is no 
cure for HIV, scientific advancements, public policies and grassroots initiatives have lead to 
strategies to prevent disease transmission and to alter the natural progression of this disease 
in those already infected. There is increasing recognition that vulnerability to HIV infection, 
access and response to treatment, and disease progression are heavily influenced by the 
social determinants ofhealth (Public Health Agency of Canada [PHAC], 2012b). 
Globally, HIV/AIDS is the leading cause of death for women of reproductive age 
(UNAIDS, 2012). Women account for 50% percent of people ofliving with HIV, and rates 
of new infections are twice as high for young females (age 15-24 years) than for similarly 
aged males (UNAIDS, 2012). Within Canada, a steady increase in the proportion of positive 
HIV tests among women has also been observed (PHAC, 2012b). Groups who appear to 
have increased vulnerability to HIV infection include Aboriginal women, women from HIV 
endemic countries and women who use injection drugs. The most common exposure 
category for Canadian women is heterosexual contact (53 .9%), followed by injection drug 
use (37.3%) (PHAC, 2012b). 
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With the introduction of highly active antiretroviral therapy (HAART) in 1996, 
the life expectancy and quality of life of individuals diagnosed with HIV has 
continuously improved and is almost that of non-HIV positive individuals (Antiretroviral 
Therapy Cohort Collaboration, 2008). However, HAART must be taken continuously, for the 
rest of an individual ' s life with a high level adherence to the medication regimen to achieve 
optimal outcomes. Additionally, like vulnerability to HIV, HAART adherence is affected by 
a variety of co-morbid conditions such as substance abuse, and mental illness, as well as by 
the social determinants ofhealth (BC-CfE, 2011). Depression is a common comorbidity 
with HIV and it both directly and indirectly impacts HIV disease progression, by 
altering biochemical progresses, psychological functioning, and HAART adherence 
(Schuster, Bornovalova, & Hunt, 2012). The intent of this paper is to review current 
literature in order to determine the role of the nurse practitioner (NP), working in British 
Columbia, in optimizing adherence to HAART amongst marginalized, HIV-positive women 
with co-morbid depression. 
Background 
Overview Of HIV I AIDS Disease Process 
There are two strains ofHIV, HIV-1 and HIV-2. HIV-1 is more virulent and 
prevalent worldwide, whereas HIV-2 is less virulent and predominantly isolated to Africa. 
(Rang, Dale, Ritter, Flower, & Henderson, 2012). This project focuses exclusively on 
individuals infected with the HIV -1 strain. HIV is a blood borne pathogen contained in 
blood, vaginal and rectal fluid, semen and breast milk. The virus is transmitted either directly 
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into the blood stream or indirectly through the highly vascular mucous membranes of the 
oral, genital or anal tract (Rote & Reuther, 201 0). Any activity where blood or body fluid is 
exchanged, such as blood transfusions, unprotected oral, vaginal or anal sexual contact, 
injection drug use or accidental occupational exposure carries the potential for infection with 
RIV. Additionally, RIV can be transmitted from mother to child (vertical transmission) 
during pregnancy and delivery, as well as breastfeeding. 
Activities that carry the highest risk for contracting RIV, from a known RIV positive 
source are injection drug use (0.67%), and receptive anal intercourse (0.5-3%) (BC-CfE, 
20 12). Risk of contracting RIV for females during penile-vaginal intercourse is 0.1 %, and 
this is twice as high as the 0.05% risk for males contracting RIV from females during penile 
vaginal intercourse (BC-CfE, 2012). The significance of this is that females are more 
susceptible to RIV infection than males during unprotected intercourse. This is particularly 
important for women who are unable to negotiated safer sexual practices due to unequal 
power relationships such as sex workers, or women in abusive relationships. 
Once in the bloodstream, RIV targets cells that express the CD4+ molecule on their 
surface, most commonly, T -lymphocytic, also referred to as helper T (Th) cells. Th cells play 
a critical role in the maturation and differentiation ofboth B lymphocytic cells, whose 
function is to produce antibodies, and T lymphocytic cells, whose role is to produce cytoxic 
cells (CD8+) responsible for directly killing antigen infected cells (Rote & Reuther, 201 0). 
Other immune cells targeted by RIV include: dendritic cells, macrophages, CD8+, natural 
killer (NK) cells, and neural cells. Infected immune cells are spread throughout the body 
through the lymphatic system (Rote & Reuther, 2010). 
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Clinically, both the absolute and fractional CD4+ counts are used for the initial 
staging ofHIV, predicting disease progression, deciding when to initiate HAART or 
opportunistic infection prophylaxis and monitoring response to therapy (BC Center for 
Excellence in HIV/AIDS [BC-Cffi], 2011). The absolute CD4+ count has traditionally been 
considered to be the best marker to monitor disease progression and response to therapy. 
However, there can be substantial individual variation due to acute illness and normal diurnal 
variation in this measure. Therefore, clinicians should be aware that changes in the absolute 
CD4+ count without corresponding changes in the CD4+ percentage, might be clinically 
insignificant (Pagana & Pagana, 2010). More stable and accurate indicators of disease 
progression are the CD4+ percentage and the CD4/CD8 ratio (Pagana & Pagana, 2010). 
Because the majority of studies that have been used to base clinical practice guidelines, use 
absolute CD4+ counts, this measure is still the most commonly used measure to guide 
therapy, monitor disease activity and assess adherence to HAART. 
Once inside the cell, HIV activates a viral enzyme, called reverse transcriptase, to 
convert the single stranded viral RNA, into double stranded DNA (Rote & Reuther, 2010). A 
second viral enzyme, integrase, inserts the viral DNA segment into the infected cell's DNA 
where it may be dormant for a period ranging from weeks to decades before becoming re-
activated. Once corrupted by viral DNA, the infected immune cell is reprogrammed to 
translate viral genetic information. HIV virons, released during lysis, destroy the infected 
immune system cell resulting in fewer functioning immune system cells (Rote & Reuther, 
2010). The plasma HIV viral load is another clinically important indicator of patient 
prognosis, disease progression and the need for antiretroviral therapy and response treatment 
(BC-Cffi, 2011). The viral load is a quantitative measure ofthe number ofvirus copies per 
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milliliter serum. The goal of HAAR T is to achieve HIV viral suppression, which is 
considered to be less than 40 HIV-RNA copies/mL (BC-CfE, 2013). Viral rebound or viral 
failure is diagnosed after two consecutive HIV-RNA viral load measurements of greater than 
200 copies/mL (BC-CfE, 20 13). Treatment failure is diagnosed if after six months of 
HAART treatment HIV-RNA load remains greater than 40 copies/mL, or if after initially 
achieving viral suppression of less than 40 copies/mL the viral load rebounds to greater than 
200 copies/mL (BC-CfE, 2013). A diagnosis of viral rebound/failure or treatment failure 
should prompt genotypic testing to detect HAART resistant HIV strains. Additionally, a full 
assessment should be completed that includes a physical exam to detect any opportunistic 
infections and a history that includes an assessment of medication side effects, drug-drug 
interactions, or recent vaccinations. As well, a thorough evaluation of psychosocial factors 
that may impact the client's adherence to HAART should be completed (BC-CfE, 2013). 
Referral to an HIV specialist is recommended for the diagnosis and management of treatment 
failure (BC-CfE, 2013). 
The replication of viral DNA is prone to errors and mutations, so the immune cells 
that were initially able to recognize and destroy HIV infected cells, fail to identify infected 
subsequently cells. Coupled with the progressive destruction of CD4+ cells, the immune 
system completely collapses (Rang et al. , 2012). In addition to the destruction of the immune 
system, a chronic inflammatory state is caused by the presence ofHIV, and viral replication. 
This state of chronic inflammation is associated with endothelial dysfunction and end organ 
damage that manifests as cardiovascular disease, renal disease or diabetes mellitus in the 
older(> 50 years) HIV -positive individuals (BC-CfE, 2011 ). These diseases are also 
associated with the long-term complications ofHAART use. As a consequence, clinicians 
must routinely screen and manage both HIV and non-HIV related conditions in the older 
HIV-positive client, who is taking HAART. 
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Clinical manifestations and progression is highly variable but a general pattern and 
correlation between viral load, CD4+ count and clinical signs and symptoms exists. The 
primary infection period generally lasts for 1 - 3 weeks after the initial infection; during this 
time HIV rapidly infects CD4+ cells and quickly reproduces viral DNA. During the primary 
infection period, between 50% and 90% of individuals report non-specific symptoms of 
fever, swollen and tender lymph nodes, malaise, myalgia, diarrhea and headaches (BC-CfE, 
2011 ). On average, these symptoms appear between 2 to 4 weeks after exposure (BC-CfE, 
2011). These flu-like symptoms spontaneously resolve and the viral load is temporarily 
reduced by the action of cytotoxic lymphocytes (Rang et al., 2012). The initial 12 weeks of 
infection are also referred to as the window period. The immune system has not yet produced 
HIV antibodies, so the HIV tests during this period may be negative even though the person 
is highly infectious. CD4+ cells have not yet been corrupted so the CD4+ count is within the 
normal range of 500- 1500 cells I mm3, however, the viral load may be extremely high with 
as many as 10 X 106 viral copies/mL (Rang et al. , 2012; New York State Department of 
Health AIDS Institute, 201 0). An estimated 50% of new HIV transmissions occur during the 
primary infection period is because the high viral load and infectiousness, continued high 
risk HIV transmission behaviors because the individual is unaware of their HIV status, and 
non-specific primary HIV infection symptoms are misdiagnosed as a non-HIV condition 
(BC-CfE, 2011). For that reason, all primary care providers should routinely screen for HIV 
in all clients, and especially for those clients presenting with non-specific, flu-like illnesses. 
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Identification of primary HIV infection is extremely challenging for health care 
providers because the prevalence of primary HIV infection among symptomatic ambulatory 
clients is relatively rare, ranging between 0.13% and 0.66% (Chu & Selwyn, 2010). Health 
care providers need to maintain a high index of suspicion for HIV when treating patients 
with influenza, or mononucleosis like symptoms of fever, myalgia, fatigue, nausea or 
vomiting, pharyngitis, headache or lymphadenopathy, and offer HIV testing. An additional 
challenge when treating patients presenting with primary HIV infection symptoms is that 
HIV testing conducted within the window period may be non-reactive, or negative. Therefore 
knowledge of testing window periods is imperative for the proper identification and 
diagnosis of primary HIV infection. This is important because it is only after a diagnosis of 
HIV that an individual can begin treatment and begin to make lifestyle adjustments to reduce 
the risk of transmitting the virus to others. 
HIV Testing in British Columbia 
In British Columbia, the initial HIV screening test is the third generation enzyme 
immunoassay (EIA) test, it detects the presence ofHIV antibodies as early as three to four 
weeks after exposure (BC Center for Disease Control [BCCDC], 2010a). The fourth 
generation EIA test is used as a supplemental test following a reactive third generation EIA. 
The fourth generation EIA has a slightly earlier window period of two to three weeks 
because in addition to testing for HIV antibodies it also tests for an HIV specific p24 antigen 
protein (BCCDC, 2010a). The BCCDC is planning to begin using the fourth generation EIA 
as an initial screening test, and some hospitals in BC are already use this test as an initial 
screening measure (BCCDC, 201 Oa). After a potential exposure to HIV, the exposed person 
should be tested, using a third or fourth generation EIA test, at time of presentation, then at 
three weeks, six weeks, six months and nine months after exposure (BCCDC, 2010b). 
Overall, more than 95% of HIV positive individuals will show detectable HIV 
antibodies by four to six weeks post infection, The gold standard confirmation of HIV 
infection seroconversion, is the Western Blot test. This test detects HIV antibodies and 
directly tests their reactivity against HIV specific proteins (BCCDC, 201 Oa). This can be 
detected as early as four to six weeks, with 99% ofHIV positive individuals having a 
positive Western Blot within three months post-exposure (BCCDC, 2010a). The individual 
RNA nucleic acid amplification test (NAA T), can be used to detect the presence of HIV 
RNA as early as one to two weeks post-exposure, as well as to confirm an HIV infection in 
individuals with indeterminate EIA or Western Blot tests (BCCDC, 2010a). 
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Current HIV screening recommendations in BC are to offer and recommend a routine 
HIV test to all adults who have not been tested in the past year when other blood work is 
ordered, when a sexually transmitted infection test or diagnosis occurs or when an HIV test is 
requested. Additionally, HIV testing may be repeated as often as every three to six months in 
patients with an identified risk, such as injection drug users or sex workers, and as part of 
routine prenatal care (HIV Testing Initiative in Family Practice, nd). The intent of these 
screening recommendations is to cast the widest net possible to identify more people earlier 
in the disease process, when viral loads and infectiousness are higher, and to initiate 
interventions to prevention transmission and slow disease progression (Gustafson & 
Steinberg, 2011). 
After the resolution of the symptoms associated with the primary HIV infection, the 
individual moves into the clinical latency period. On average, this asymptomatic period lasts 
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approximately 10 years. Unfortunately, during this asymptomatic period, the virus is 
constantly replicating and gradually destroying CD+ cells. Consequently the person is 
infectious, able to unknowingly transmit HIV to others, and suffering progressive damage to 
their immune system and ultimately developing AIDS. A diagnosis of AIDS requires a 
confirmed HIV infection and either a CD4+ count less than 200 cells/mm3, or the presence of 
one or more, AIDS defining illnesses (BCCDC, 2013; Alberta Health Services, nd). 
Examples of AIDS defining illness include: bronchial, tracheal, pulmonary or esophageal 
candidiasis, Kaposi's sarcoma, recurrent bacterial pneumonia or pneumocystis jiroveci 
pneumonia and chronic intestinal cryptosporidiosis (Alberta Health Services, nd). Early 
diagnosis and treatment of HIV can reduce transmission risk, substantially improve the 
quality oflife ofPLWHA, and prevent the progression to AIDS. 
Provincial HIV I AIDS Programming 
British Columbia's HIV/AIDS programming is guided by the BC-CtE. The 
cornerstone ofBC's HIV/AIDS programing is Treatment as Prevention (TasP). Pioneered by 
BC-CtE physician and researcher Dr. Julio Montaner, TasP operates on the premise that the 
concentration ofHIV DNA in blood and body fluids is directly correlated with the likelihood 
of transmitting HIV (BC-CtE, 2013). As will be more completely discussed in the next 
seCtion, decreasing the viral load ofHIV-positive individuals through the use HAART drugs, 
has the potential to curb the spread ofHIV. In 2009, BC's Ministry of Health launched a four 
year, $48-million pilot project called Seek and Treat for Optimal Prevention ofHIV/AIDS 
(STOP HIV/AIDS) in Vancouver and Prince George. The goals of the pilot were to increase 
HIV screening and testing to identify HIV positive individuals, and to increase the number of 
HIV positive individuals being treated with HAART (STOP HIV/AIDS, nd). Due to the 
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success of the STOP HIV/AIDS pilot project the provincial government has renewed funding 
of $19.9 annually for the next four years and expanded the program to the entire province 
(BC-CfE, 2013, April). Additionally, HAART medications are provided free of cost to all 
HIV positive individuals who meet the treatment criteria in the BC-CfE Therapeutic 
Guidelines, and who are either a BC resident with Medical Services Plan (MSP) coverage, or 
have Interim Federal Health coverage (refugee status) or have active medical plan coverage 
from another Canadian Province, while awaiting active MSP coverage (BC-CfE, nd). 
Within Prince George, BC, the Medication Adherence Support Program (MASP) 
provides "an intensive seven day-a-week medication adherence support program for people 
living with HIV, HCV and tuberculosis, who are struggling with adherence ... " (Northern 
Health [NH], 2012, p. 5). HIV-nurse clinicians provide nursing services including blood 
collection, dressing changes, support and advocacy. Additionally, an on-site HIV -pharmacist 
is available for medication reconciliation and support. MASP also includes both a safe 
physical space where clients can come to use the shower or laundry facilities, as well as, 
mobile outreach services and text-based medication reminders and support (NH, 20 12). 
Highly Active Antiretroviral Therapy (HAART) 
Today, the foundation ofHIV treatment is HAART. Since HAART was first 
introduced in 1996, it has demonstrated the ability to inhibit viral replication and thus 
decrease plasma viral load to nearly undetectable levels. The caveat to HAART is that 
because HIV is never completely eradicated from the body, interruptions in therapy are 
associated viral load rebound, and increased risk of HAAR T resistance strains of HIV (BC-
CfE, 2011). There are several benefits of decreased viral load, first, immune system function 
is improved thereby reducing the risk of opportunistic infections, improving the quality of 
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life and decreasing the mortality rates of individuals infected with HIV (Montaner et al., 
2006). For example, prior to the availability ofHAART, the average life span of a 20 year-
old diagnosed with HIV was 56.1 years in developed countries. Since the advent ofHAART 
an HIV-positive person can expect to live to at least age 69.4 years (Antiretroviral Therapy 
Cohort Collaboration, 2008). Unfortunately, this is still 12 years less than the average life 
span ofnon-HIV positive British Columbians (Province of British Columbia, 2013). The 
second benefit of decreased viral load is a reduction in systemic inflammation caused by 
uncontrolled immune system activation. Systemic inflammation is associated with end organ 
damage, and may play a role in the early development of cardiovascular disease, renal 
disease, cancer and neurocognitive decline in HIV -positive individuals (BC-CfE, 2013, 
February). 
Finally, by reducing the plasma viral load to virtually undetectable levels, 
transmission of HIV from mothers to infants, shared needles, and between 
uninfected/infected (serodiscordant) couples is dramatically reduced. For example, the 
sexual transmission of HIV in serodiscordant, heterosexual couples is reduced by 96% when 
HAART is used (BC-CfE, 2013). Ultimately, this has the potential to slow the spread ofHIV 
within entire populations, not just at the individual level (Montaner et al., 2006). For 
example, BC witnessed at 52% reduction in HIV transmission, between 1996 and 2009, that 
is largely attributed to expanded access to HAART, as well as other harm reduction 
initiatives, such as safe injection sites, and needle exchange programs (Montaner et al., 
2010). As ofMay 2013 , in BC, there were a total of6 374 individuals receiving HAART, of 
these 1 035 are female (BC-CfE, 2013, May). As of January 2013 , within the Northern 
Health Authority there are a total of229 PLWHA, and 185 (80.8%) are receiving HAART 
(Hamour, 2013). 
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Antiretroviral medications. Individuals who have previously been treated with 
HAART, who have experienced treatment failure, or other serious HAART related 
complications are too complex for primary management by a nurse practitioner and should 
be referred for care by an HIV specialist physician (BC-CfE, 2011). For individuals who 
have never received HAART, first line medications typically consists of a combination of 
three antiretroviral drugs, two nucleoside/nucleotide reverse transcriptase inhibitors (nRTis), 
combined with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI) (BC-CfE, 2013). In this section these three classes of drugs will be briefly 
discussed with an emphasis on the recommended first line choices for treatment na!ve 
individuals. 
Nucleotide reverse transcriptase inhibitors. Nucleotide reverse transcriptase 
inhibitors (nRTis) form the backbone ofHAART. They are transformed into an active 
molecule during intracellular phosphorylation. Once active, they become incorporated into 
the viral DNA chain and inhibit the binding of the enzyme transcriptase, resulting in 
termination of DNA chain synthesis and ultimately, decreased viral DNA production (Safrin, 
2004). Resistance may develop because viral replication is rapid and prone to errors that 
allow nRTI resistant strains to spontaneously develop. Additionally, poor HAART adherence 
increases the likelihood that resistant nR TI strains are allowed to replicate, causing treatment 
failure and potentially to be transmitted to other individuals. As a class, the most serious 
adverse effect ofnRTis is mitochondrial toxicity. It arises from the incidental inhibition of 
the host's mitochondrial DNA polymerase by the active phosphorylated nRTI compound 
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(Rang et al., 2012). Potentially life-threatening manifestations of mitochondria toxicity 
include myopathy, peripheral neuropathy, hepatic steatosis and lactic acidosis (Rang et al., 
2012). Other common unwanted side-effects associated with nRTis include nausea, 
vomiting, abdominal pain, anemia or neutropenia, insomnia, dizziness and headache (Rang et 
al. , 2012). Emtricitabine is a frequently used nRTI that is used in first-line combination drugs 
Truvada and Atripla. It is important to note that females are particularly likely to report 
unwanted side effects such as rash and gastrointestinal disturbance (BC-CfE, 2013, 
February). Tenofovir disoproxil fumarate (TDF) is generally well tolerated but long-term 
use, and/or concurrent with Pis or other nephrotoxic medications such as non-steroidal anti-
inflammatory drug, has been associated with renal injury and should be avoided in patients 
with renal disease (BC-CfE, 2013 , February). Another nRTI is abacavir (ABC), prior to 
initiating this drug, screening for the HLA-B*5701 allele must be completed. This is because 
individuals who possess the HLA-B*5701 allele are at increased risk for developing a 
potentially life-threatening hypersensitivity reaction (BC-CfE, 2013, February). Additionally, 
ABC may be associated with an increased risk of myocardial infarction (MI), and as such 
should be avoided inpatients with cardiovascular disease (BC-CfE, 2013 , February). In BC, 
the recommended first line dual nRTI combination drug is Truvada, (tenofovir 
/emitricitabine), a non-nephrotoxic alternative is Kivexa (abacavir I lamivudine), ifHLA-
B*5701 negative (BC-CfE, 2013, February). Both regimens are taken as a once daily, fixed 
dose, without any food restrictions (BC-CfE, 2013, February). 
Non-nucleoside reverse transcriptase inhibitors. NNRTis bind at a site close to, but 
distinct from nR Tis. They prevent the HIV -1 reverse transcriptase enzyme from adding 
nucleotides to the DNA strand, resulting in decreased viral replication (Rang et al., 2012). 
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The first line recommended NNRTI, for treatment naive individuals is Efavirenz (BC-CfE, 
2013, February). Common side effects include rash, fever, headache, insomnia, nightmares, 
anxiety, liver damage, lipodystrophy and pancreatitis. When considering the use of these 
drugs with co-morbid depression, it is important to note that approximately 50% of patients 
treated with Efavirenz experience psychiatric side effects such as increased anxiety, 
depression and suicidal ideation (Watkins, Pieper & Treisman, 2011). These psychiatric side 
effects are usually temporary lasting for the first four to six weeks of drug therapy. Efavirenz 
is also not recommended for use during the first trimester of pregnancy and women of 
childbearing age, who do not use reliable contraception because it is teratogenic (BC-CfE, 
2013 , February). The care ofHIV-positive women who are pregnant or who are planning on 
becoming pregnant should be conducted with expert guidance such as that available through 
the Oak Tree Clinic at BC Women's Hospital (BC-CfE, 2013, February). Additionally, 
NNRTis are most commonly associated with drug resistance due to poor adherence and 
transmission of drug resistant strains ofHIV (BC-CfE, 2013, February). Efavirenz is a once 
daily medication best taken on an empty stomach at bedtime. There are several multi-drug 
combination products that allow for more convenient once daily, single tablet dosing. For 
example, Atripla is the recommended first-line dual nRTI (tenofovir I emtricitabine) and 
NNRTI (efavirenz) combination drug (BC-CfE, 2013, February). 
Protease inhibitors (Pis). Pis prevent the binding of the protease, an enzyme 
responsible for cleaving HIV-1 or HIV-2 precursors into active proteins. This results in the 
creation of immature, non-infectious viral particles (Safrin, 2004). Recommended dual Pis 
are atazanavir /ritonavir, and is taken as a once daily dose, preferable with food (BC-CfE, 
2013, February). Common unwanted side effects associated with Pis include nausea, 
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vomiting, abdominal pain, anemia or neutropenia, hyperglycemia, non-pathologic jaundice, 
elevated transaminase, impaired renal function, kidney stones (Rang et al., 2012; BC-CfE, 
2013, February). 
Two additional classes of drugs that may be used as part ofHAART therapy include 
integrase strand transfer inhibitors, and entry inhibitors. They will not be discussed as part of 
this paper because drugs from these classes should be reserved only for those clients who are 
unable to tolerate, or who have experienced treatment failure on the preferred first-line 
regimens (BC-CfE, 2013, February). As well, these more complex individuals should be 
followed and managed by an HIV specialist physician, with additional collaboration or 
consultation with an HIV specialist pharmacist. 
Highly Active Antiretroviral Therapy Adherence 
In order for HAAR T to achieve the ultimate goal of sustained, suppressed viral load, 
an extremely high level(~ 95%) of medication adherence is required (BC-CfE, 2011). 
Clinically, optimal HAAR T adherence is reflected as a plasma viral load of less than 40 
copies I mL, when measured using polymerase chain reaction assay, or less than 75 copies I 
mL, when branched DNA test is used (Harris, Montessori, & Montaner, 2011). Suboptimal 
adherence (80-95%) is associated with an increased likelihood of viral resistance to HAART, 
increased morbidity and mortality, and the transmission of drug-resistance HIV strains 
(O'Neil et al., 2012). Failure of viral suppression is represented by the inability to maintain 
HIV RNA levels below 200 copies I mL (BC-CfE, 2013, February; Harris et al., 2011). 
While it is difficult to determine actual adherence rates ofHAART, it is generally accepted 
that adherence is approximately 50% (Duggan, Lochear, Fink, Okonta, & Chakraborty, 
2009). This is significantly less than the optimal 95% adherence rates required for optimal 
clinical outcomes. As well, the public health concern is that HAAR T resistant HIV strains 
may become more prevalent, thus limiting the HAAR T treatment options to regimens that 
contain drugs with poorer safety and tolerability profiles. 
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Even though pharmaceutical advancements have dramatically decreased the daily 
number of pills and the side effects associated with _HAART, these medications are not 
without significant side effects, and they must be taken everyday, without interruption, for 
the rest ofthe individual's life. Factors such as patient readiness, pill burden, depression, 
drug and alcohol abuse, and medication side effects strongly affect HAART adherence 
(Duggan, Lochear, Fink, Okonta, & Chakraborty, 2009). Additional social and 
environmental factors that influence HAART adherence include gender, stable housing, 
income, participation in the sex trade, incarceration, family dynamics, access to health care 
and medication, and continuity of relationship with a health care provider (Werb et al., 
2012). In much the same way that research has revealed that vulnerability to HIV infection is 
influenced more heavily by social and environmental factors than by individual choice, so 
too is vulnerability to HAART non-adherence (Krusi, Wood, Montaner, & Kerr, 2010). 
Unfortunately, the incredible complexity, and interaction of the factors affecting adherence 
has made it difficult for researchers to make specific recommendations to improve HAAR T 
adherence in women. In BC, it is recommended that depression, substance abuse and other 
mental health conditions receive high priority as part of the care plan for individuals 
receiving HAART (BC-CfE, 2011). 
Depression and HIV I AIDS 
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The intent of this paper is to examine depression in the context of HIV infection and 
HAART treatment and adherence. Depression affects between 37.6-48.6% of people living 
with HIV, making it one of the most common comorbidities associated with HIV infection 
(O'Neil et al., 2012). Depression not only negatively impacts an individual's quality oflife, it 
also predicts a three-fold increase in the likelihood of HAAR T non-adherence and poorer 
clinical outcomes, as measured by CD4+ and viral load (Gonzalez, Batchelder, Psaros, & 
Safren, 2011; Schuster et al., 2012). Additionally, there is evidence to suggest that depressed 
HIV-positive individuals are more likely to initiate HAART at a later stage with lower CD4+ 
counts and higher viral loads, two factors associated with poorer treatment outcomes (Tegger 
et al., 2008). Many of the symptoms of depression, outlined below, are also associated with 
HIV disease progression, and HAART medication side effects (Schuster, Bomovalova, & 
Hunt, 2012; Carrico et al., 2011). This is of importance to primary care providers because, as 
will be discussed in later sections, the identification and subsequent treatment of comorbid 
depression improves overall quality of life, and may increase HAAR T adherence and HIV 
treatment outcomes. 
A diagnosis of depression, is made, if over the same two-week period, at least five of 
the follow symptoms are present on most or nearly every day: 
• Depressed mood nearly every day 
• Markedly decreased interest or pleasure in activities 
• Greater than 5% unintentional change in body weight 
• Insomnia or hypersomnia 
• Psychomotor agitation or retardation 
• Fatigue or loss of energy 
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• Feelings of worthlessness or excessive or inappropriate guilt 
• Diminished ability to think or concentrate, indecisiveness 
• Recurrent thoughts of death, recurrent suicidal ideation with or without a specific 
plan, or suicide attempt (American Psychological Association [APA] , 2013) 
Additionally, for a diagnosis of depression, these symptoms must cause significant 
distress or impairment in social, occupational or other areas of functioning (APA, 2013). In 
the context ofHIV, depression negatively impacts an individual's ability to cope with the 
challenges associated with being HIV positive such as stigmatization and medication 
. adherence (Bianco et al. , 2011). For NPs working with HIV-positive clients in primary care 
settings, identification and treatment of comorbid depression is an important intervention to 
optimize HAAR T adherence and improve the quality of life. In BC, NPs are able to 
independently diagnose, treat and manage depression (CRNBC, 2012). 
Nurse Practitioners 
In BC, physicians are the main primary care providers who initiate and monitor 
HAART. However, nurse practitioners (NPs), competent in HIV/AIDS care, and in 
collaboration with an experienced physician can diagnose HIV I AIDS and renew existing 
HAART prescriptions (BC-CfE, nd; CRNBC, 2011). NPs are included under the umbrella 
term, advanced practice nurses, and have been practicing in BC since 2005. They are 
registered nurses, who have, most commonly, completed a graduate degree in nursing and 
have demonstrated proficiency during both practical and written examinations. There are 
three classifications, or streams, of practice for NPs in BC: family, adult and pediatric. An 
NP is able to independently diagnose and treat certain diseases and conditions as specified by 
CRNBC's document Scope of Practice for Nurse Practitioners: Standards, Limits and 
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Conditions (2012). NPs collaborate with physicians, and other health care professionals 
when they are treating patients with diseases or conditions that fall outside of their scope of 
practice, or when they require support or guidance for diseases with which they are 
unfamiliar. The intent of the NP role is to increase access to primary care services for all 
British Columbians. 
The foundation of practice and core competencies ofNPs is the World Health 
Organization's (WHO) five principles of primary health care (PHC): accessibility, public 
participation, health promotion, appropriate technology and intersectoral collaboration 
(Canadian Nurses Association [CNA], 2009; CRNBC, 2011, January). PHC is both a 
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philosophy and model for health care delivery. PHC attempts to answer the question, "Why 
treat people, without changing what is making them sick (WHO, 2012)?" It recognizes that 
health and well-being are affected by factors lying both inside and outside the health care 
sector. These factors that are outside of the health care sector are referred to as the social 
determinants ofhealth. In Canada, the social determinants ofhealth include gender, income, 
race, Aboriginal status, food insecurity, job security, early childhood development, housing, 
social exclusion and social safety networks (Mikkonen & Raphael, 201 0). 
The four categories ofCRNBC's NP competency framework are: 1) professional 
role, responsibility, and accountability, 2) health assessment, 3) therapeutic management, and 
4) health promotion and prevention of injury (CRNBC, 2011, January). This research project 
will be approached from a PHC stance and the discussion will be organized according to 
CRNBC's NP competency framework. Structuring this research project within a PHC 
framework will help to ensure that this project will treat the problem of low HAART 
adherence amongst HIV -positive women with comorbid depression, in a holistic and 
complete manner. Organizing the findings according to the competency framework will 
ensure that the role of the NP will be comprehensively explored. 
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CHAPTER TWO 
Literature Search Strategy 
The overarching question for this project is, what is the role of the nurse 
practitioner, working in British Columbia, in optimizing adherence to HAART amongst 
marginalized, HIV-positive women with co-morbid depression? In order to address this 
question, the following sub-questions were explored: 
• How can depression be identified, treated and evaluated by NPs working with 
HIV positive women? 
• How can the treatment of depression by NPs be incorporated into strategies to 
improve HAART adherence that are currently being utilized in British Columbia? 
Background information was researched guided by another set of sub-questions: 
• What is the prevalence of HIV in Canada? 
• What is the prevalence of comorbid depression among HIV-positive 
individuals? 
• What is the effect of comorbid depression on HAART adherence among HIV-
positive individuals? 
• What are the effects of comorbid depression on HIV-positive women? 
• What are the major risk factors for comorbid depression among HIV-positive 
women? 
The literature search was initiated with a hand search of articles already 
collected during the completion of other assignments that were part of this program. 
Next, relevant websites, such as, the BC Center for Excellence in HIV /AIDS, Public 
Health Agency of Canada, World Health Organization, The Body Pro, CATIE and 
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Canadian HIV I AIDS Pharmacists Network, were reviewed in an effort to obtain grey 
literature sources, and to familiarize myself with current research priorities and 
recommendations. The literature search was conducted using University of Northern 
British Columbia and Northern Health Authority libraries. Online computerized 
databases CINAHL, MEDLINE, Cochrane Reviews, and PubMed were searched using 
various combinations of the following search terms: HIV, AIDS, women, female, 
marginalization, Canada, British Columbia, highly active antiretroviral therapy, 
medication compliance, medication adherence, nurse practitioner, depression, mental 
health, and chronic disease. 
Ancestry searching of the most recent and relevant articles was used to locate 
additional articles. Finally, key search terms, the names of frequently cited authors and 
study names, for example, 'LISA', were searched in Google, to obtain additional grey 
literature materials. Once saturation had been achieved, articles were then scanned and 
included or excluded according to the criteria summarized in Table 1. Because HIV care 
and HAART are rapidly evolving, the decision was made to limit articles to those 
published in the last five years in an effort to capture to most current snapshot of 
HAART adherence research. Similarly, studies were included only if the data set was 
from after 1996, when antiretroviral drugs entered the arena of HIV care. 
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Table 1 
Literature Search Inclusion and Exclusion Criteria 
Inclusion Exclusion 
Published after 2008 Published before 2008 
Published in English Published in language other than English 
Research studies of any type Non-research articles 
Research conducted in Canada or USA Non-Canadian or American research 
Data used in study was from after 1996 Data used in study was from prior to 1996 
Study population included females Study population included only males 
Topic of research was relevant to primary Topic of research was not relevant to 
care and/or nurse practitioner practice primary care and/or nurse practitioner 
practice 
Summary of Articles Retrieved 
Once the articles were collected and included or excluded according to the 
criteria specified in Table 1, they were read and categorized according to themes. The 
dominant research themes that emerged were: incidence and prevalence of HIV in 
Canada, incidence of comorbid depression with HIV, effect of depression on HIV disease 
progression and adherence, factors correlated with comorbid depression and HIV, and 
management of HIV and comorbid depression. Table 2 summarizes the number of 
articles retrieved and analyzed according to each theme, with some articles fitting into 
more than one theme. 
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Table 2 
Articles Retrieved Categorized According to Themes 
Major Theme Number of Articles Retrieved 
Incidence and prevalence of HIV in Canada 6 
Incidence of depression in people with HIV I AIDS 18 
Effect of co morbid depression on HIV disease 13 
progression and adherence 
Factors correlated with depression in people living 20 
with HIV/AIDS 
Management HIV and comorbid depression 25 
Total articles retrieved 82 
CHAPTER THREE 
Literature Search Findings 
Incidence and Prevalence ofHIV/AIDS in Canada 
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As of 2011 , the estimated prevalence of people living with HIV I AIDS (PL WHA) in 
Canada is 71 300, this represents an 11.7% increase since 2008 (PHAC, 2012a). There are 
approximately 16 600 Canadian women living with HIV (PHAC, 2012b). Heterosexual 
contact and injection drug use are the two most common exposure categories for Canadian 
women (PHAC, 2012b). Within BC, there are an estimated 11 700 PLWHA (BC Center for 
Disease Control [BCCDC] , 2012). The incidence of new HIV infections in Canada has 
remained relatively stable with an estimated 3 175 new infections in 2011 , compared with 3 
335 new infections in 2008 (PHAC, 2012a). The literature has suggested that advances in 
HIV treatment have reduced the mortality ofHIV, thus allowing an increase in the 
prevalence without a corresponding increase in transmission rates (PHAC, 2012a). In 2011 , 
BC reported 289 new positive HIV tests, ofthese 24 (female= 10) were from Northern 
Health Authority (NHA); this represents the lowest incidence in the last three decades of this 
epidemic (BCCDC, 2012). Currently, in NHA there are approximately 220 PLWHA 
(Hamour, 2013). Consistent with overall exposure categories for the province, injection drug 
use is the predominant exposure category within NHA. The dramatic decrease in the 
incidence of HIV in BC is largely attributable to a reduction in HIV transmission amongst 
people who use injection drugs (BCCDC, 2012). The proportion of new HIV diagnoses due 
to injection drug use (IDU) has decreased from 30%, in 2008, to 12.1% in 2011(BCCDC, 
2012). 
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It is also important to discuss HIV I AIDS among Aboriginal people in Canada. Over 
the last decade, it has been observed that Aboriginal people are over-represented in the 
number of new diagnoses ofHIV. HIV infection risk is estimated to be 3.6 times higher for 
Aboriginal people compared to non-Aboriginal people (PHAC, 2010). In 2008 there was an 
estimated 4 300-6 100 HIV-positive Aboriginal people, which represents a 24% increase in 
from 2005 estimates. Of these 1 691 lived in British Columbia (Hogg, Strathdee, Kerr, 
Wood, & Remis, 2005; PHAC, 2010). Among Aboriginal people, injection drug use was the 
predominant HIV transmission category and accounted for 66% of new diagnoses (PHAC, 
2010). When examining a population of injection drug users in Vancouver, BC, Wood et al. 
(2008) found that the prevalence of HIV among Aboriginal people was significantly higher 
than among non-Aboriginal people (16.0% versus 25 .1%; P< 0.001). Aboriginal women are 
disproportionately represented in the number of positive HIV tests. Women represented 
48.1% of positive HIV tests within the Aboriginal population by comparison; in non-
Aboriginal Canadian populations women represent only 20.7% of new diagnoses (PHAC, 
2010). 
Incidence of Depression in People Living with HIV I AIDS 
A challenge that emerged in interpreting the research findings for this project relates 
to the fact that a wide variety of depression rating scales were utilized. As well, depression 
scores may be inflated because of the similarity between the cognitive and somatic 
symptoms of HIV disease progression, medication side effects and depression (Lima et al., 
2007). However, both somatic and cognitive symptoms improve with depression treatment 
(Ferrando & Freyberg, 2008). The most frequently utilized scale was the Center for 
Epidemiologic Studies Depression Scale (CES-D). The CES-D was originally designed as a 
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research tool for use in non-psychiatric community samples and it commonly over estimates 
the prevalence of clinical depression in a population (Lima et al., 2007). Crane et al. (20 1 0) 
validated the use of the Patient Health Questionnaire (PHQ-9) for use in clinical settings 
PL WHA but cautioned that differences were observed between African and Caucasian 
Americans, and results were not stratified by gender. Additionally, there are cultural 
differences in how depression is manifested in the clinical setting. Cain et al. (20 11) found 
that Aboriginal people rarely used the term 'sadness' to describe their depression and that 
they associated social isolation and disconnection with depression more often than 
psychological feelings or mood. Additionally, Logie, James, Tharao, and Loutfy (2013) 
suggest that African, Caribbean and Black women may conceptualize depression differently, 
and that conventional depression screening tools may not accurately assess depression in 
these populations. 
In addition to dissimilar depression rating scales, there is a wide variation in the 
estimates of depression among PLWHA due to varied population characteristics and time 
since diagnosis with HIV. Despite this variation, there was consistency in the findings that 
depression is significantly more prevalent amongPL WHA, that women tend to experience 
depression more frequently than men, and that depression is associated with decreased 
adherence to HAART. In a longitudinal cohort study of 1 774 HIV-positive males and 
females, Teggar et al. (2008) found that 57% had a diagnosis of either depression or. other 
mood disorder. Tedaldi et al. (2012) found that depression was significantly more prevalent 
among women (21.9%) compared to men (11.8%, p=0.005). Likewise, Applebaum, 
Richardson, Brady, Brief and Keane (2009) found that 77% of women, compared with 44% 
(P = 0.11; P< 0.05) ofmen were depressed, in a study of67 HIV-positive outpatients. In a 
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longitudinal study, using data from the Women' s Interagency HIV Study (WIHS), Kapadia 
et al. (2008) found that 47% (p < 0.001) ofwomen enrolled in a drug abuse treatment 
program were classified as having significant depressive symptoms. Bhatia et al. (20 11) 
found that in the 180 days immediately following diagnosis with HIV, 67% of people 
screened positive for depression and that women were more likely to be depressed than men 
(X2 = 4.2, P=0.04). In the longitudinal observational study, Kacanek et al. (201 0) found that 
22% of PL WHA, without a history of depression, developed depression during the yearlong 
study period. Additionally, they found that women (37%) were significantly more likely to 
develop depression than men (18%; P=0.005) (Kacanek et al., 201 0). 
A study conducted by Logie et al. (2013) with a population of 173 HIV-positive, 
African, Caribbean and Black women in Ontario, found that 65% of study participants met 
the criteria for depression. In a study conducted in BC, 50% of HIV -positive individuals, 
enrolled in a drug treatment program, had significant depressive symptoms (Zhang et al., 
20 12). Results of another British Columbian study found that longitudinally tracked 
depression amongst participants ranged between 37.6% and 48.6% (O'Neil et al., 2012). 
Unfortunately the results were not stratified by gender, but the overall prevalence of 
depression in this population is similar to that of other studies conducted with PL WHA 
enrolled in substance abuse treatment programs. 
A large gap in the literature is in research examining HIV, depression and HAAR T 
adherence among Aboriginal people. Depression and suicide among Aboriginal people is a 
serious concern because many Aboriginal communities experience rates significantly higher 
than the general Canadian population. For example, 21% oflow-income Aboriginal people 
experienced depression, compared with 13% oflow-income non-Aboriginal people (Reading 
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& Wien, 2009). Because poorly treated depression is a risk factor for suicide, it is important 
to note that suicide rates among First Nations youth are five to six times higher than non-
Aboriginal people (Health Canada, 2013). Cain et al. (2011) found that half of the 72 HIV-
positive Aboriginal people with comorbid depression, had either attempted or had recurring 
thoughts of suicide. By comparison, in an American study of 514 non-Aboriginal PLWHA, 
15% reported having suicidal thoughts in the two weeks prior to the study period (Shacham, 
Nurutdinova, Satyanarayana, Stamm & Overton, 2009). 
There is a large and rapidly evolving body of research examining the relationships 
between social determinants ofhealth, colonization, the residential schooling legacy and 
Aboriginal health and wellness (Pearce et al. , 2008). However, it is well beyond the scope of 
this project to thoroughly examine this fascinating body of knowledge. My intent is to draw 
attention to the idea that given the high prevalence of depression and suicide among non-HIV 
positive Aboriginal people, it is conceivable that depression among HIV -positive Aboriginals 
may be significantly higher as well. However, this literature search did not result in resources 
that supported this supposition. 
This literature search found that HIV-positive individuals are two to four times more 
likely to suffer from depression than the general population, that depression rates are highest 
in the period after diagnosis with HIV, and that women are more likely to experience 
depression (Bhatia et al. , 2011; Kacanek et al. , 201 0). There is evidence to indicate that the 
prevalence of depression among HIV -positive women ranges between 3 7% and 65% 
(Kacanek et al. , 2010; Logie et al. , 2013). However, there is a gap in the literature examining 
depression among HIV -positive women, and research that examines depression among HIV-
positive Aboriginal people is essentially absent. 
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Effects of Co-morbid Depression on HIV Disease Progression and HAART Adherence 
In the literature, evidence of adherence was measured either directly or indirectly. 
Direct measures of adherence include pill counts, electronic pill cap monitoring and self-
reported adherence. A caution when interpreting the results of studies that used these direct 
measures of adherence is that, because the subjects knew they were being evaluated, their 
behavior may have changed. Additionally these strategies were only employed for a limited 
amount time, so researchers may have missed changes in adherence over time. Indirect 
measure of adherence entailed analyzing biochemical markers of HIV disease, such as CD4+ 
count and viral load. Unfortunately, because these biochemical markers of HIV represented 
the cumulative effect of all factors in an individual's life, including adherence, a direct causal 
link with adherence could only be implied. However, from a clinical perspective a clinician 
may find it useful to use both direct and indirect measures to assess HAART adherence. 
Barriers associated with the clinical use of direct measures include the associated costs of 
administering electronic pill cap monitoring systems or clients forget to bring in their 
medications for pill-counts. Fortunately, in BC, all HAART medications are dispensed from 
a central pharmacy operated by the BC-CfE, this means that HIV clinicians can readily 
assess whether or not a client has at least obtained their medications according to schedule. 
Biochemical effects of depression on HIV/AIDS. Review of the retrieved studies 
revealed that depression directly affects HIV disease progression by altering the 
physiological functioning of the immune system. In their systematic literature review, Gore-
Felton and Koopman (2008) concluded that after controlling for adherence and substance 
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abuse, depression was directly correlated to biochemical markers of HIV disease 
progression. Schuster, Bornovalova and Hunt (2012) frame the discussion ofthe biochemical 
response to depression around dysregulation ofthe hypothalamic-pituitary-adrenal (HPA) 
axis. Physical and emotion stresses, such as depression, trigger the hypothalamus to release 
corticotrophin releasing hormone, which in turn stimulates the pituitary to release 
adrenocorticotropic hormone (ACTH). ACTH stimulates the adrenal cortex to secrete 
cortisol. Elevated cortisol impairs immune function by releasing inflammatory cytokines, 
triggering immune cell death, impairing T -cell production by the thymus, and inhibiting 
release of interleukins and interferon, which impairs lymphocytic response by natural killer 
(NK) cells to antigens (Schuster, Bornovalova, & Hunt, 2012). The net result ofHPA axis 
mediated immune dysfunction is increased HIV replication leading to further destruction of 
CD4+, NK and other immune system cells and ultimately progression to AIDS. This 
relationship is partially illustrated by Carrico et al. (2011) who found that depressive 
symptoms predicted a 50% increase, from baseline, in mean HIV viral load, after controlling 
for CD4+ count at baseline. Tedaldi et al. (2012), found that depression was significantly 
associated with CD4+ count < 200 cell/mm3; however, they did not find a statistically 
significant correlation between depression and viral load. In a study of 127 IDUs, Springer, 
Chen and Altice (2009) found the improvements in depressive symptoms were significantly 
correlated with improvements in CD4+ counts and adherence. Conversely they found that 
worsening depressive symptoms were significantly associated with decreased CD4+, 
increased viral load, homelessness, female gender, poor self-efficacy, and use of illegal drugs 
(Springer, Chen & Altice, 2009). Psychological stress, such as depression, triggers HP A axis 
dysfunction, which in turn causes impaired immunologic response to HIV infection and is 
associated with increased viral loads and poorer clinical outcomes. 
Psychological Effects of Co morbid Depression 
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Five studies were retrieved that specifically examined the relationship between 
depression, behavior, psychosocial factors and HAART adherence. Wagner et al. (2011), 
sought to determine whether somatic or cognitive symptoms of depression differentially 
predicted non-adherence. The authors concluded that adherence, measured directly via 
electronic pill cap monitoring, negatively correlated with depression (r = -0.08; p<0.01) in a 
population ofHIV-positive males and females. With further analysis they found that 
HAART non-adherence was significantly correlated with the following cognitive symptoms; 
depressed mood, loss of interest, hopelessness, guilt, poor concentration and a sense of 
worthlessness. The only somatic symptom of depression to significantly correlate with non-
adherence was fatigue. Additionally, the authors found that their model fit when tested in a 
cross-sectional multivariate analysis against a number of different variables including race, 
sexual preference and gender (Wagner et al., 2011). 
Dilorio et al. (2009), found that depression and poor self-efficacy, significantly 
predicted non-adherence, measured through a self-report questionnaire, in a mixed gender 
sample of PL WHA. They further added that poor social support strongly predicted increased 
levels of depression. Social support was described as, "having someone to share activities 
with, to work out a plan with, who lets me be myself, and who loves and cares (Dilorio et al., 
2009, p. 16)". They also found that stigma and satisfaction with medical care were directly 
related with self-efficacy, and self-efficacy was inversely correlated with depression. 
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Likewise, Cha, Erlen, Kim, Sereika, and Caruthers (2008), found that depressive symptoms 
did not directly influence self-reported HAART adherence, rather depression negatively 
impacted self-efficacy beliefs, which in tum determined whether or not an individual would 
be adherent to HAART. They also found that poor social support strongly predicted 
increased likelihood of depression in this sample ofHIV-positive males and females (Cha et 
al., 2008). 
Wendorf and Mosack (2013) found that the effect of depression on HAART 
adherence was mediated by coping strategies. Depression, along with HIV -related cues, and 
health and self-care belief, determined an individual's coping style. HIV-related cues were 
referred to as any illness cues related to HIV disease progression or treatment such as 
intrusive side effects, stigma, medication reminders, or disappointing clinical results 
(Wendorf & Mosack, 2013 ). Higher levels of depression were associated with negative, or 
avoidance, coping strategies. A voidance oriented coping strategies were directly correlated 
with HAART non-adherence (Wendorf & Mosack, 2013). They described depression as 
decreasing an individual's ability to respond to the challenges associated with living HIV. 
Similarly, Bianco, Heckman, Sutton, Watakasol and Lovejoy (2011), found that avoidance 
coping strategies, and poor social support significantly predicted depression among older (> 
50 years) HIV-positive males and females. 
In the only study retrieved that did not find any correlation between depression and 
adherence in male or female subjects, Applebaum et al. (2009), found that unwanted 
medication side-effects and alcohol use more strongly predicted non-adherence amongst 
HIV -positive women. While they found that depression affected 77% of females, compared 
to 44% of males, they did not find any significant differences between genders with respect 
to adherence. The authors suggest that this finding may be due to characteristics of the 
sample population such as participation in a comprehensive HIV program that emphasized 
mental health and positive health practices (Applebaum et al. , 2009). 
Interestingly, despite the similarities in the findings on the relationship between 
psychosocial factors and depression in these five studies, they diverged when assessing 
whether depression predicted HAART non-adherence. Whereas Wendorf and Mosack 
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(20 13 ), Dilorio et al. (2009), and Cha et al. (2008), found that depression correlated with 
HAART adherence among males and females, Bianco et al. (2011) did not find a significant 
correlation between depression and adherence amongst older HIV -positive women, but they 
did find a correlation amongst HIV -positive men. It is possible that the contrasting findings 
from these studies are due to the influence of the male gender in the studies by Wendorf and 
Mosak (2013), and Dilorio et al. (2009) or yet unknown characteristics ofHIV positive 
females. The contrasting findings from these studies illustrates the importance of research 
that stratifies findings according to gender, as well as research specifically examining co-
morbid depression in HIV-positive women. 
Depression impacts the progression of HIV in two ways. First it directly precipitates 
dysregulation of the HP A axis, which causes subsequent immunologic dysfunction. Second, 
it indirectly causes shifts in cognitive, emotional and behavior functioning that predispose an 
individual to become non-adherent with HAART. Non-adherence to HAART is associated 
with unchecked viral replication and hastened decompensation of the immune system. 
Depression is associated with decreased CD4+ counts and elevated viral loads, both 
indicators of HIV disease progression. The next section will discuss factors that are 
associated with comorbid depression. 
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Factors Correlated with Comorbid Depression 
Much of the evidence found that depression was a risk factor associated with 
numerous biological and psychosocial factors related to HAART non-adherence. Analysis of 
the research revealed that many of the same risk factors related to increased susceptibility to 
contracting HIV, are also linked to increased risk of depression and HAART non-adherence. 
The biggest challenge that emerged in analyzing the research was interpreting the results to 
determine whether depression was an exposure risk or an outcome. This is because the 
majority of the studies were observational retrospective cohort studies, where significant 
depression was an incidental finding not necessarily the focus of the study. 
Tedaldi et al. (2012) extensively examined depression in the context ofHIV, and 
found that women were significantly more likely to experience depression than men, and 
they also correlated increased risk of depression with having no marital/sexual partner, being 
heterosexual, using injection drugs, being co-infected with Hepatitis C, and personal or 
family history of depression. In another study that specifically examined factors correlated 
with depression, Bhatia et al. (2011) found that in addition to being associated with female 
gender, depression directly correlated with income < $25 000, recent substance abuse, poor 
access to medical care, and low self-efficacy. As the risk factors for depression were not 
stratified by gender, caution should be used when interpreting these findings because readers 
are unable determine if any ofthese factors affect women differently than men. 
There were a number of studies conducted using data from the Longitudinal · 
Investigations into Supportive and Ancillary Health Services (LISA) cohort. The LISA 
cohort is particularly relevant to this paper because it is largely representative of the people 
receiving HAAR T in BC since 1996, including marginalized people such as women and 
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those who self-identify as Aboriginal (Palmer et al. , 2011). Palmer et al. (2011) found that 
4 7% of study participants had negative body image. Within the population of people with 
negative body image they also found that 49.76% (p<O.OOl) also reported high levels of 
stigma and depression. Unfortunately, the authors analyzed stigma and depression as a single 
variable, so it is difficult to determine the impact depression alone had on body image, or if 
stigma affected depression and vice versa. Blashill, Gordon and Safren (2012), studied a 
mixed gender sample of 89 PL WHA with opioid-dependence, and found that concerns about 
physical appearance were associated with increased depression and anxiety. Unfortunately, 
neither of these studies stratified the results by gender, however, they were included in this 
project because of the consistency in the relationship between body image and depression. 
Additionally, lipodystrophy, a redistribution of fat away from the face and deposition on the 
abdomen and trunk, is associated with both HIV disease progression as well as HAART side 
effects. 
In another study with the LISA cohort, Parashar et al. (20 11 ), found that among 
participants who had unstable housing, 70.3% also had depressive symptoms, compared to 
50.8% of participants who had stable housing (P < 0.001). Additionally, they found that 
adherence among people who were unstably housed was 45.3%, compared to 62.7% (P 
<0.001) among stably housed HIV-positive individuals. This study did not find gender to be 
a significant predictor of homelessness or depression, nor did it reveal whether depression 
was a cause or effect ofhomelessness or unstable housing. Nonetheless this is an important 
study because it demonstrates the impact socioeconomic factors have on the mental and 
physical wellbeing of people living with HIV/AIDS. This study, as with the next study to be 
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discussed, highlights the importance of addressing the social and structural factors as well as 
factors within an individual's control when addressing HAART adherence. 
In the final study using data from the LISA cohort, Anema et al. (20 11) found that 
71 % of participants experienced food insecurity. Among those who were food insecure, 
66.7% also experienced depression, compared to 33.8% (p<0.0001) ofthose who had food 
security (Anema et al., 2011). Food insecurity is also closely associated with unstable 
housing, for example only 16% of unstably housed people were food secure compared to 
50.8% (P < 0.001) of those who were stably housed (Parashar et al. , 2011). By comparison, 
food insecurity among the general British Columbian population is estimated at 8.4% (Health 
Canada, 2012). Given that food insecurity is related to decreased adherence, lower body 
mass index, lower odds ofviral suppression and increased risk of mortality, it is vitally 
important to assess food security among all HIV-positive individuals, but especially those 
who are unstably housed and depressed. 
Nicotine dependence was found to significantly correlate with depressive symptoms 
in a study examining the relationship between nicotine dependence and HAART adherence 
by Webb, Vanable, Carey, and Blair (2009). Richardson et al. (2009) found a correlation 
between pain frequency and severity, depression, and longer duration of tobacco dependence. 
They found that depression significantly and directly correlated with the severity of pain. 
They also found that severe pain correlated with both a history of crack/heroin use, and with 
IDU as the mode of HIV transmission (Richardson et al. , 2009). Findings by Tedaldi et al. 
(2012) supported this association between depression and nicotine dependence. While the 
mechanism linking depression with nicotine use is not clear, it is important to note that 
nicotine dependence is associated with increased rate of depression, pain severity and 
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frequency, and non-adherence to HAART (King et al. , 2012). It is suggested that nicotine 
dependence is an indicator of other socioeconomic factors such as poverty and low literacy 
that influence depression risk and HAART non-adherence (King et al. , 2012; Webb et al., 
2009). 
Boarts, Buckley-Fischer, Armelie, Bogart and Delahanty (2009) examined depression 
in a population of HIV -positive individuals who also had a diagnosis of post-traumatic 
stress disorder (PTSD). In the sub-population of people with PTSD attributed to HIV 
diagnosis, 69.2% met the criteria for depression, and in the sub-population with non-HIV 
related PTSD 78.3% met the criteria for depression (Boarts et al. , 2009). When examining 
HAAR T adherence rates Boarts et al. (2008), found that adherence over time improved 
among the sub-population with HIV -related PTSD, whereas adherence deteriorated over time 
in the sub-population with PTSD related to other traumas. The importance of PTSD is 
highlighted when examining the incidence ofPTSD and depression among women IDU. 
Amongst a population of HIV -positive Canadian African, Caribbean and Black 
women, Logie et al. (2013) found that racial and gender discrimination had a significant 
positive correlation with depression. They additionally found that the most significant 
predictor of depression was HIV-related stigma, and was significantly correlated with racial 
and gender discrimination. The influence of stigma on depression was also found among 
HIV-positive Aboriginal people. Cain et al. (2013) found that stigmatization contributes to 
the development of depression among Aboriginal PL WHA. Sources of stigmatization 
include being Aboriginal in dominant non-Aboriginal Canadian society, as well as 
stigmatization related to being HIV positive by their communities, family and friends (Cain 
et al., 2013). 
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Interestingly, Cain et al. (2011), found that among HIV-positive Aboriginal people, 
the diagnosis of HIV was not the primary source of depression. Participants described 
racism, poverty, drug and alcohol use, childhood abuse, lack of housing and unemployment 
as key factors contributing to their depression, and that their depression was the underlying 
cause of behaviors that put them at risk for contracting HIV. This finding supports the idea 
that increased vulnerability to HN among Aboriginal people is not based on individual 
choices or characteristics, rather it represents the cumulative effect of colonization, 
residential schooling legacy and social and economic marginalization (Pearce et al. , 2008). 
In a study by Eiboff, Somers and Moniruzzaman (2012), they found that among the 
133 female participants, 72.7% of injection drug users met the criteria for depression, 
compared with 43.0% of non-injection drug users. Additionally, they found that PTSD 
occurred more frequently in female injection drug users (54.5%) than female non-injection 
drug users, and overall, the prevalence of depression and PTSD in females was higher than in 
males. Nolan et al. (2011) found that in the first year ofantiretroviral treatment, only 30.3% 
ofiDUs were~ 95% adherent to HAART. Of those who were adherent to HAART, 80.8% 
achieved HIV RNA suppression, whereas only 28.9% in the non-adherent group achieved 
viral suppression (Nolan et al. , 2011). While the studies reviewed for this project did not 
reveal a causal link between depression and IDU, the high prevalence of depression and the 
low levels of adherence among IDUs make this an important population in the discussion of 
depression and HAART adherence. Furthermore, because injection drug use is one of the 
leading HIV exposure categories for both Aboriginal and non-Aboriginal women, HAART 
adherence is vitally important as part of the BC-CfE's Treatment as Prevention program to 
slow the spread of HIV by decreasing the prevalence of HIV at the population level 
(Montaner, 2010; O'Neil at al., 2011; PHAC, 2010). 
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There are numerous psychosocioeconomic factors associated with comorbid 
depression among HIV -positive individuals. The most obvious gap in the literature retrieved 
for this project is the limited number of studies that examined depression in females. Factors 
associated with comorbid depression among HIV -positive women include: injection drug 
use, discrimination, acute or chronic pain, PTSD, social support, and avoidance coping. 
Additional factors among both HIV -positive males and females include: poverty, relationship 
status, hepatitis C co-infection, personal or family history of depression, body image, 
unstable housing, food insecurity, nicotine dependence, self-efficacy and stigma. These 
psychosocial and economic factors are similar to the factors that increase vulnerability to 
HIV. 
Depression has both a direct and indirect negative impact on HIV disease progression 
through its effect on immunological function, and cognitive, emotional or behavioral 
functioning that increase the likelihood of HAAR T non-adherence. Adherence to HAAR T is 
crucial at the individual level for decreasing HIV related morbidity and mortality, as well as 
at the population level to slow the spread of the virus. The next section will discuss strategies 
to treat depression among HIV-positive individuals in an effort to improve quality oflife by 
decreasing depressive symptoms, as well as to increase adherence to HAART. 
Management of HIV and Comorbid Depression in Primary Care 
This literature search revealed a paucity of studies that investigated improving 
HAAR T adherence among HIV -positive women, with comorbid depression. Two clinical 
practice guidelines were retrieved that specifically addressed co-morbid depression among 
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people living with HIV/AIDS (PLWHA). Six interventional studies were retrieved, however, 
only three of these directly addressed depression among HIV-positive individuals, and none 
of these studies stratified the results by gender. My literature search findings are supported 
by a systematic review that examined interventions for the treatment of HIV and depression 
published in 2009 that found only 6.7% (n=97) of the studies exclusively used women, none 
of these studies met the inclusion criteria for this project (Sherr, Clucas, Harding, Sibley, & 
Catalan, 2011). In an opinion piece, Monforte et al. (2010), remark that women comprise less 
than 20% of participants in clinical trials, except for those trials evaluating vertical (mother 
to fetus) HIV transmission, and that this proportion is declining. The concern with the lack of 
studies involving HIV -positive women, is that females exhibit behavioral, cultural, and 
physiological differences from men that may result in different pharmacological effects and 
responses to HAART and antidepressant therapy (Montforte et al., 2010). However, due to 
the scarcity of research investigating HIV -positive women with comorbid depression, the 
studies discussed in this section reflect research conducted on predominantly male 
populations. 
Screening and identification of depression. The New York State Department of 
Health AIDS Institute (20 1 0), recommends that clinicians screen clients for depression, at 
least annually, and whenever depression symptoms are identified, with the following two-
question screen: 
• During the past month, have you often been bothered by feeling down, depressed 
or hopeless? 
• During the past month have you been bother by little interest or pleasure in doing 
things? 
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If the client answers "yes" to either of these questions, then a more detailed 
evaluation using a validated depression rating scale is recommended. Commonly used 
depression rating scales include the CES-D, Beck Depression Inventory (BDI), Patient 
Health Questionnaire 9 (PHQ-9), and Hamilton Rating Scale for Depression (HAM-D/HDI). 
No specific recommendations were found indicating a superior depression rating scale, rather 
it was suggested that clinicians use a single rating scale best suited to their practice style and 
client characteristics (Relf, Eisbach, Okine & Ward, 2013). As discussed in an earlier 
section, an official diagnosis of depression is made using the diagnostic criteria specified in 
the DSM-V. 
Non-pharmacologic interventions. Cognitive behavioral therapy (CBT) was the 
most commonly investigated non-pharmacological intervention for PLWHA with co-morbid 
depression. CBT is a short-term psychotherapy, which can be conducted in both individual 
and group settings. It focuses on the relationship between one's thoughts, feelings and 
actions. Through a series of 10 - 12 sessions participants are given strategies to change their 
patterns of behavior, thoughts or feelings that are contributing to and engraining their 
depression (Safren, Gonzalez & Soroudi, 2008). Safren et al. (2009) conducted a 
randomized controlled trial (RTC) that compared the effect of cognitive-behavioral therapy 
for HIV medication adherence and depression (CBT-AD) to the effect of a single session for 
adherence and letter to their physician documenting their diagnosis with depression. The 
authors did not stratify the results by gender. Regardless, they found that the CBT -AD group 
demonstrated improvements in HAART adherence, as well as decreases in both depressive 
symptoms and viral load. These improvements were maintained over 6 and 12-month follow-
up. In a similar study conducted with HIV-positive injection drug users, Safren, O'Cleirigh, 
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Bullis, Stein, and Pollack (2012), found significant improvements in adherence and CD4+ 
counts, as well as decreases in depressive symptoms. However, in this study the authors 
found that these gains were not maintained beyond the 3, 6 or 12-month follow-ups. They 
recommend that amongst PLWHA who use injection drugs, CBT-AD, be continued beyond 
the usually 10-12 sessions (Safren et al. , 2012). The efficacy ofCBT is supported in the 
systematic review of the literature examining interventions for HIV and depression by Sherr 
et al. (2011), who found that psychological interventions, specifically CBT, was consistently 
the most effective. 
Access to counseling services may be limited by availability, location or cost in many 
communities. Referral to an AIDS Service Organization (ASO) for additional support may 
be a strategy to access counseling services, as well as, receive peer and social support, 
HIV/AIDS education, and addictions counseling (BC-CfE, 2011; Positive Living North 
[PLN], nd). Additionally, ASOs may also participate in leadership, community HIV I AIDS 
advocacy and educational activities (PLN, nd). Another important community resource for 
any HIV-positive individuals struggling with HAART adherence are programs such as the 
Medication Support and Adherence Program, where clients can receive specialized HIV 
support as well as, access to a safe, clean environment. 
Other non-pharmacologic interventions that may be of use with PLWHA with co-
morbid depression include mindfulness-based stress reduction (MBSR) therapies such as 
yoga, meditation and breathing exercises (Relf, Eisbach, Okine & Ward, 2013). Hand, 
Lyerly, Jaggers, and Dudgeon (2009) conducted a systematic review of the literature 
investigating the effect of exercise on HIV -positive individuals, and found moderate-
intensity aerobic exercise consistently decreases symptoms of depression and anxiety, but 
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had no effect on HAART adherence or CD4+ count or viral load. The authors suggest that 
physical inactivity and associated deconditioning may exacerbate HIV disease and treatment 
related symptoms such as fatigue and lipodystrophy factors associated with HAART non-
adherence. 
Pharmacological interventions. There was a significant amount of research 
examining the role and effectiveness of antidepressants in the care of HIV-positive 
individuals with comorbid depression. When discussing pharmacotherapy for depression, it 
is important to remember that psychotherapy combined with antidepressant therapy is the 
most effective regimen for most patients, and that for many clients with mild-moderate 
depression psychotherapy alone may be as effective as medications (New York State 
Department of Health AIDS Institute [NYHAI], 2010). An additional consideration is that 
the primary health care approach requires that clinicians also attend to the predisposing 
factors for depression such as poverty, unstable housing, substance abuse and food 
insecurity. Antidepressant therapy without concurrent strategies to improve an individual's 
social determinants of health is unlikely to provide lasting and effective results. 
As previously mentioned, enrollment ofHIV-positive women in HIV related clinical 
trials is low. Females comprise less than 20% of participants in clinical trials, despite 
representing 50% of the worldwide HIV-positive population (Monforte, 2010). No studies 
were retrieved for this project that examined the effects of antidepressants among female 
participants. Again, due to the lack of existing evidence, findings for pharmacologic 
interventions will be extrapolated to females from studies conducted with predominantly 
gay/bisexual male participants. No evidence was found indicating that antidepressants were 
ineffective with HIV-positive individuals. In the studies retrieved treatment with 
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antidepressant medications were associated with decreases in depression symptoms, and 
some studies found improvements in CD4+ count and viral loads, and adherence to HAAR T 
medications. Selective serotonin reuptake inhibitors (SSRis) and tricyclic antidepressants 
(TCAs) are the most commonly researched antidepressants for use with HIV-positive 
individuals. 
Cruess et al. (2012), found that adherence was significantly higher among depressed 
PL WHA prescribed psychotropic medications, including antidepressants, compared with 
those who were not prescribed any psychotropic agents. Similarly, Tsai et al. (20 1 0), found 
that antidepressant use was associated with a 25% increase in self-reported HAART 
adherence and 1.55 greater odds in achieving viral suppression among unstably housed or 
homeless participants. They suggested that the improvements in viral suppression were 
related to improved medication adherence and increased participation in HIV care services. 
In a related study, Tsai et al. (2013) compared the effect of directly observed fluoxetine 
delayed release (once weekly) with the effect of referral to a community psychiatric program 
for unstably housed or homeless depressed HIV-positive individuals. Interestingly, the 
authors found that depression severity was significantly reduced with fluoxetine use, but 
there was no significant change in HIV RNA levels or HAART adherence. The authors 
attribute their small sample size with the statistically insignificant effect of Fluoxetine on 
HAART adherence in this study. Even though findings were not stratified by gender in any 
of these studies, these findings are relevant to this project because they address comorbid 
depression among HIV -positive people who are unstably housed or homeless, a risk factor 
for depression among women. 
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Horberg et al. (2008), specifically examined the effect ofSSRis on HAART 
adherence and found that individuals who were >80% adherent to SSRI regimen exhibited 
statistically similar HAART adherence and viral control as non-depressed HIV-positive 
individuals. The authors also found that people with comorbid depression, who were 
adherent to SSRis, had greater improvements in CD4+ counts than untreated depressed HIV-
positive people. This study also demonstrated that untreated depression significantly reduces 
the likelihood of achieving viral suppression. Kumar and Encinosa (2009) also found that 
treatment of depression, regardless of the treatment used, is associated with improved 
HAART adherence, comparable to the adherence rates ofnon-depressed HIV-positive 
people. They also found a direct correlation between the degree of depression and HAART 
non-adherence. 
Safety and prescribing considerations for pharmacologic treatment of depression. 
It is beyond the scope of this paper to conduct an in depth discussion on the potential adverse 
interactions between HAAR T and antidepressants, or to review all the antidepressants 
available for use, but a brief overview is warranted for the purposes of this project and safe 
NP practice. The foundation of most drug-drug interactions involves cytochrome P450 
(CYP450), a family of enzymes responsible for the metabolism of most medications. 
Medications can either induce or inhibit the CYP450 enzymes. If two or more drugs use the 
same CYP450 pathway, significant drug-drug reactions may occur because drug metabolism 
is altered and this may lead to toxic, or sub-therapeutic serum levels (Lynch & Price, 2007). 
In PL WHA the consequences may be drug discontinuation, viral load rebound or the 
development of resistant HIV strains (Tseng et al., 2012). Protease inhibitors, such as 
Ritonavir, are the most common HAART medication implicated in drug-drug interactions. 
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Ritonavir is a potent inhibitor of CYP450 enzymes, and most commonly results in increases 
in the serum levels of the concomitant drug, although serum levels ofRitonavir may also be 
increased to toxic levels with some drug combinations. For example, serum levels of SSRis 
and TCAs metabolized via the CYP450 pathway are increased and this increases the risk of 
serotonin syndrome and TCA toxicity (NYHAI, 2010; HRSA, 2011). Other Pis and 
Efavirenz (NNRTI) may decrease the serum levels of other antidepressants such as 
paroxetine, sertraline and buproprion (HRHS, 2011). St. John's Wort, a popular herbal 
medication used to treat depression, is contraindicated for those using Pis and NNR Tis 
because it can decrease the serum levels of these medications contributing to treatment 
failure and the development ofHAART resistant HIV strains (HRSA, 2011). 
Management of drug interactions may involve increasing or decreasing medication 
dosages, or completely avoiding certain combinations. There are several challenges to 
monitoring for potential drug interactions. First, PharmaNet, BC's prescription monitoring 
system does not include HAART medications on client's profiles (Kreutzwiser, 2013). The 
implication for both practitioners and clients is that if a client receives medical care outside 
of their HIV clinic, they may be unknowingly prescribed inappropriate medications. Primary 
care providers should counsel clients on this potential risk if they seek medical care outside 
of their regular primary care clinic. Due to concerns about inadvertent disclosure of HN-
positive status and HIV-related stigma, the inclusion ofHAART medications on PharmaNet 
needs further consideration. The second challenge with HN care is that the field ofHN-
related medication interactions is rapidly evolving and much of the information in standard 
drug references is out of date by the time the reference becomes available. Collaboration and 
consultation with a specialized HN pharmacist is recommended to decrease the risk of 
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clinically significant negative drug-drug interactions, decrease the risk of adverse drug 
reactions, and promote adherence to HAAR T (Health Resources and Services Administration 
HIV/AIDS Bureau [HRSA], 2011; Tseng et al., 2012; BC-CfE, 2013). The BC-CfE offers 
the Rapid Expert Advice and Consultation in HIV line, a 24-hour, toll-free hotline (1 800 
665 7677) available for primary care providers to consult with HIV-specialist pharmacists or 
physicians. As well, it is recommended that practitioners use current resources to investigate 
potential drug interactions such as those available through British Columbia Center for 
Excellence in HIV (BC-CfE), Toronto General Hospital Immunodeficiency Clinic, or the 
AIDSinfo Drug Database (Tseng et al., 2012). 
No direct comparison studies were retrieved comparing the efficacy of SSRis, with 
TCA or serotonin-norepinephrine reuptake inhibitors (SNRis). Selection of antidepressants 
should be guided by other properties of the drug such as sedation or activation qualities, 
weight gain or appetite suppression (Watkins, Pieper, & Treisman, 2011). SSRis are the 
recommended first line medication for the treatment of depression due to safety 
considerations such as adverse effects and medication interactions (Freudenreich et al., 201 0; 
NYHAI, 2010; Relfet al., 2013; Watkins et al., 2011). Specifically, Citalopram and 
Escitalopram may be reasonable first-line choices because enzymes of the CYP450 family do 
not metabolize them, so drug interactions with HAAR T medications are reduced (NYHAI, 
2010). 
Regardless of the antidepressant selected, the general principle for prescribing is to 
start at a low dosage and slowly titrate up until a therapeutic effect is achieved (Relf et al., 
2013; Adams et al., 2013; HRSA, 2011). In the initial phase oftreatment frequent 
appointments are recommended to monitor for adverse medication effects, drug-drug 
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interactions, tolerability, adherence and response to treatment (HRSA, 2011). Adams et al. 
(2012) developed an algorithm for antidepressant management by HIV clinicians. They 
recommend appointments to monitor for side effects every other week, and dosage 
adjustments, based on results of a validated depression rating scale, to occur every four to six 
weeks. Other guidelines recommend more frequent appointments, every one to two weeks, 
and more aggressive titration of medications to occur every two to four weeks if no adverse 
side effects are reported (GPAC, 2004; HRSA, 2011). Once the client has achieved 
resolution of depression symptoms, follow-up is recommended monthly to every other month 
for the duration of treatment. Generally, it is recommended that the duration of 
pharmacologic treatment for depression range between six to 12 months, with some 
individuals requiring life-long treatment (Freudenreich et al., 201 0). Discontinuation of 
antidepressants due to remission of depression should be done as a gradual taper to avoid 
withdrawal or return of depressive symptoms (HRSA, 2011). 
If after a four to six week therapeutic trial with antidepressants, the client has not 
experienced a significant reduction or complete resolution of depressive symptoms the 
clinician should consider a dosage increase or switching to a different antidepressant (HRSA, 
2011; Freudenreich et al. , 201 0). For clients who do not experience any improvement in 
depressive symptoms, Freudenreich et al. (2010), suggest that acceptable second line 
treatments include switching to an SNRI (venlafaxine), a novel action antidepressant 
(bupropion), or a different SSRI, such as sertraline. When switching antidepressants 
clinicians should refer to clinical practice guidelines, such as the Guidelines and Protocols 
Advisory Committee (GPAC) Depression, for specific recommendations regarding washout 
periods. For clients who experience a partial resolution of symptoms, clinicians may consider 
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adding a second antidepressant from a different class (Freudenreich et al., 2010). Again, 
choice of a second line agent should be based on side-effect profile, potential drug 
interaction, and cost. Referral to psychiatry should be considered for all patients with severe 
depression, those with a high degree of suicidal ideation or intent, and those who do not 
exhibit a response to a therapeutic trial of antidepressant therapy. Additionally, referral to 
psychiatry should be made if there is uncertainty about the diagnosis or the presence of other 
mental illnesses, such a bipolar disorder or schizophrenia (NYHAI, 201 0). Primary care 
providers should maintain contact and coordinate care with the psychiatrist or mental health 
clinician throughout the treatment course in an effort to maintain a relationship with that 
client and to attend to the client's other medical needs (NYHAI, 201 0). 
Models ofHIV care delivery. With the advent ofHAART, the prevalence of 
comorbidities and mortality associated with HIV I AIDS has changed from predominantly 
opportunistic infections, to cardiac disease, diabetes, renal failure and non-HIV related 
cancers (Chu & Selwyn, 2011). The care ofHIV positive people is shifting away from a 
HAART focused model with intense specialization and medicalization ofHIV care, towards 
care that requires the management of multiple chronic diseases and other primary care needs. 
As HIV care becomes increasingly complex due to the presence of multiple chronic 
comorbidities, rapidly evolving HAART technology and the increased potential for adverse 
events related to polypharmacy, both specialized HIV clinicians, and generalist primary care 
providers struggle with the increasingly complex needs ofHIV-positive clients (Chu & 
Selwyn, 2011). This section explores models ofHIV care with potential to improve the 
outcomes ofHIV-positive people with comorbid depression. There is a large body of 
literature examining HIV care models in the context of highly specialized American HIV 
care clinics, but very few studies were found that examined models of care in primary care 
settings, with clients with comorbid depression or in Canadian settings. 
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A collaborative care model to manage depression within HIV specialty clinic was 
examined by Pyne et al. (2011). They compared depression severity, medication adherence 
and HIV symptoms severity in a RCT comparing collaborative care with usual care among a 
population of clients selected from a Veterans HIV clinic. Usual care involved screening, 
treatment and management of depression by the HIV -care specialist. The collaborative care 
model in this study involved a dedicated HIV depression care team consisting of a clinical 
pharmacist, a psychiatrist and a registered nurse case manager, who saw clients over a period 
of 12-months. This team communicated with the HIV-care specialist through an electronic 
medical record and weekly client care conferences. Clients who received care from the 
collaborative care team experienced improvements in their depression symptoms, but there 
was no statistical improvement in the severity of their HIV-related symptoms, or HAART 
adherence (Pyne et al. , 2011 ). 
Measurement-based care (MBC) is another model for depression treatment currently 
being evaluated for use within HIV specialty clinics as part of the SLAM DUNC study that 
will be completed in 2014 (Pence et al. , 2012). The MBC approach has been shown to 
decrease depression severity, significantly improve CD4+ counts and decrease HIV viral 
load among a sample of 124 HIV positive clients (Coleman, Blashill, Gandhi, Safren, & 
Freudenreich, 2012). MBC is an evidence-based model of care that guides the pharmacologic 
management of depression in areas where access to specialized mental health clinicians is 
limited (Adams et al. , 2012). Within the MBC model registered nurses, social workers or 
other trained team members use clinically validated tools to measure symptoms, assess 
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response to treatment and antidepressant tolerability. The non-psychiatric specialist 
prescriber uses this information to inform their clinical decisions. One of the promising 
features .ofMBC for depression is that it can be integrated into existing multi-disciplinary 
health clinics, without hiring new staff, or requiring clients to travel to a different location for 
services. The treatment algorithm recommended for use with HIV-adapted MBC is evidence-
based and incorporates the choice of 6 antidepressants ( citalopram, escitalopram, sertraline, 
mirtazapine, bupropion and venlafaxine) that are safest for use with HAART and have the 
most tolerable side effect profiles (Adams et al. , 2012). The findings of the SLAM DUNC 
study are expected in late 2014 and may lead to the development of comprehensive clinical 
practice guidelines or recommendations for the treatment of comorbid depression. 
The next two studies to be discussed did not meet the inclusion criteria because 
depression was not specifically addressed, but have been included in this study, because the 
research was conducted in Prince George, BC and the findings are of relevance to the larger 
picture of providing primary health care services to marginalized populations. Tu et al. 
(2013) explored the use of a Chronic Care Model (CCM) in an effort to improve HIV care 
among a predominantly Aboriginal population. CCM is flexible organizing framework based 
on six modifiable elements ofhealthcare delivery: organizational support, clinical 
information systems, healthcare delivery system design, decision support, client self-
management support and community resources. The goal of CCM is "to promote uptake of 
evidence-based clinical recommendations, enhance clinical teamwork, and empower patients 
to better manage their own care" (Tu et al. , 2013 , p.652). They found that the use of CCM 
was associated with significant improvements in HAAR T uptake, and increases in viral load 
suppression rates among individuals on HAART. As well, the authors found significant 
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improvements in other measure such as rates of pneumococcal immunization, syphilis and 
tuberculosis screening (Tu et al., 2013). It is also important to note that the BC-CfE endorses 
the use of a CCM in the provision of holistic, interdisciplinary HIV care (BC-CfE, 2011 ). 
The relevance of these findings to this project is that because CCM encourages the adoption 
of clinical practice guidelines and encourages practitioners to identify patients in need of 
care, there is the potential that clinical practice guidelines for the screening and treatment of 
depression might successfully be integrated into the model. 
The final study to be discussed takes an even broader look at health care delivery 
amongst marginalized populations in BC. Browne et al. (20 12) examined how the delivery of 
primary health care services to marginalized populations could be improved through an 
equity-oriented primary health care model. Although this study does not specifically address 
HIV or depression it is relevant to this project because the findings suggest how primary 
health care systems can address the social and structural determinants ofhealth among 
marginalized populations. Four key elements comprise the foundation of an equity-oriented 
PHC model. These key elements include: inequity responsive care, trauma and violence 
informed care, contextually tailored care and culturally competent care (Browne et al., 2012). 
The authors further suggest 10 strategies to directly address inequities in the social 
determinants of health and barriers to accessing PHC among marginalized individuals. These 
findings are important to consider in the context of HIV care because, as discussed earlier in 
this paper, vulnerability to HIV infection and disease outcomes are heavily influenced by the 
social determinants ofhealth. 
Summary of Literature Findings 
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The body of research evaluated for this project revealed a startling lack of studies 
conducted with female participants. As well as a conspicuous absence of studies involving 
NPs or NP practice. Evidence in the literature demonstrates that while overall HIV 
transmission rates are declining for the general Canadian population, transmission rates 
among marginalized groups such as Aboriginal people and women are increasing (PHAC, 
2012b). HAART has improved the morbidity and mortality ofHIV-positive people, however, 
it requires a high level adherence(~ 95%) to be optimally effective. Overall, adherence to 
HAART is estimated to be approximately 50%. The concern with non-adherence is the risk 
for the development and transmission of HAAR T resistance HIV strains, and unsuppressed 
viral replication that ultimately could result in opportunistic infections and AIDS. A variety 
of socioeconomic factors including unstable housing, poverty drug and alcohol abuse, and 
depression are associated with increased risk of poor HAAR T adherence. 
The incidence of depression is two to three times higher among HIV -positive people, 
and women were more likely to experience comorbid depression. This is concerning because 
depression is associated with worse disease outcomes, decreased adherence to HAAR T 
regimens and poorer quality oflife. Factors associated with comorbid depression include: co-
infection with hepatitis C virus, injection drug use, nicotine dependence, poverty, food 
insecurity, personal or family history of depression, PTSD, stigma, racial and gender 
discrimination, lipodystrophy, and unstable housing or homelessness. 
HIV -positive people respond as well to conventional pharmacologic and non-
pharmacologic treatments for depression as non-HIV positive people. Cognitive behavior 
therapy and treatment with antidepressants were shown to effectively treat depressive 
symptoms and improve HAAR T adherence. However, clinicians need to exercise caution in 
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the clinical application of research findings to female populations because the vast majority 
of studies were conducted with male participants. In an effort to improve the overall quality 
of life by reducing depressive symptoms and improving HAAR T adherence, clinicians 
should diligently screen and treat depression. Routine screening for depression, using a 
clinically validated tool, and monitoring for symptoms of depression should occur at least 
yearly and whenever symptoms suggestive of depression are present. CBT is the most 
commonly researched non-pharmacologic therapy for the treatment of depression. When 
considering pharmacological treatment for depression, health care providers need to be 
vigilant for potential drug interactions between HAAR T and antidepressants. Due to 
concerns of drug interactions and efficacy, recommended first-line treatments for depression 
are from the SSRI family, citalopram and escitalopram. Collaboration with an HIV specialist 
pharmacist is recommended to reduce the occurrence of drug-drug interactions and adverse 
side effects. 
Studies investigating models of care designed to treated depression amongst HIV-
positive individuals were scarce. Collaborative and measurement based care models were 
shown to be effective strategies to deliver depression treatment and management within HIV 
specialty care clinics. The chronic care model and an equity-oriented primary health care 
model were discussed. These studies did not meet the inclusion criteria but were included 
because the research was conducted locally within Prince George, BC and they approached 
the provision of care from a holistic stance and encouraged providers to address the social, 
structural and environmental determinants of health that influenced individual and 
community health status. 
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CHAPTER FOUR 
Discussion: Role of the Nurse Practitioner 
The aim of this project is to answer the question, "What is the role of the NP, 
working in BC, in optimizing adherence to HAART amongst marginalized, HIV-positive 
women with comorbid depression?" A literature search was conducted and it was found that 
treatment with cognitive behavioral therapy or antidepressants can both improve depressive 
symptoms and improve HAAR T adherence. This literature search found, that among HIV-
positive women, injection drug use, racial or gender discrimination, chronic pain, post-
traumatic stress disorder, poor social support and avoidance coping strategies were 
associated with increased risk of comorbid depression and HAART non-adherence (Bianco 
et al. , 2011; Eiboff et al. , 2012; Logie et al. , 2013; Richardson et al., 2009; Tedaldi et al. , 
2012) . In an effort to determine the role ofthe NP, these literature findings will be discussed 
in the context of the following four key competencies required ofNP practice in BC 
(CRNBC, 2013): 
• Establish and maintain professional role, responsibility, and accountability 
• Assess and diagnoses client health/illness status 
• Therapeutically manage health care 
• Promote health and prevent illness/injury 
When attempting to elucidate the role of the NP in caring for female, HIV-positive 
clients with comorbid depression, three challenges emerged. First, no studies were retrieved 
that directly addressed NP practice, second, little evidence was found to indicate effective 
strategies primary care providers can utilize when attempting to address the social 
determinants ofhealth and finally, there was little evidence involving female, HIV-positive 
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participants. This is significant because not only do NPs have the legislated authority to 
provide collaborative care for HIV-positive clients, they also posses knowledge of health 
policy reform, community development and health program planning that provides them with 
the tools to directly address these social issues affecting the health of their clients. As well, 
the lack of research with female participants may mean that uniquely female factors that 
influence HIV-disease progression or HAART adherence are not identified and understood. 
Fundamental to NP practice is the expectation that the NP integrates awareness about the 
social determinants of health, cultural safety and diversity throughout all aspects of client 
care (CRNBC, 2010). Browne and Tarlier (2008) suggest that the key to NP role 
sustainability in Canada is the ability ofNPs to transform awareness of the social 
determinants of health into action. This is particularly important when one considers that 
vulnerability to contracting HIV, as well as, adherence to HAART and overall disease 
outcomes, are strongly associated with the social determinants of health. Therefore, potential 
strategies, based on findings from this literature search, to address the social determinants of 
health that will allow NPs to attend to these social issues will be interwoven throughout this 
discussion in an effort to highlight the contributions NPs make in the care of HIV -positive 
women with comorbid depression. 
Professional Role, Responsibility and Accountability 
This competency addresses activities aimed at optimizing the delivery of primary 
care services to individuals and communities, as well as, guiding continuing competency and 
research projects (CRNBC, 2013). Three of the key activities associated with the 
professional role, responsibility and accountability competency are (a) practicing within 
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scope of practice, (b) collaboration, consultation and referral and to (c) engaging in relevant 
research activities (CRNBC, 2013). 
Practicing within scope of practice. NPs have the legal authority and educational 
background to safely care for HIV-positive women with comorbid depression. In BC, the NP 
scope of practice stipulates that if a "nurse practitioner establishes or strongly suspects a 
diagnosis" ofHIV, the NP should consult with a physician to confirm the diagnosis and/or 
develop a management plan (CRNBC, 2013, p.27). Additionally, NPs are able to 
independently diagnose and treat depression in adults (CRNBC, 20i3). Part of the graduate 
level education for NPs includes the development of skills needed to research, critically 
appraise and apply literature relating to clinical practice issues such as HAART adherence. 
Staying abreast of current research is vitally important for NPs working with HIV -positive 
clients who are receiving HAART because of the rapidly changing research in the fields of 
HIV prevention and treatment. In addition to utilizing current clinical practice guidelines 
such as BC-CfE's Primary Care Guidelines for the Management ofHIV/AIDS in British 
Columbia (2011, March) and the Therapeutic Guidelines: Antiretroviral (ARV) Treatment of 
Adult HIV Infection (2013, February), the NP is expected to take additional training to attain 
and maintain competence in HIV I AIDS care. CRNBC and BC-CfE recommend that NPs 
who wish to practice in the field ofHIV care or have at least five HIV-positive clients in 
their care, take a clinical course such as the John Ruedy Immunodeficiency Clinic 
Preceptorship Program for Nurse Practitioners (CRNBC, 2012; BCCfE, nd). HIV-positive 
clients cared for by competent NPs receive primary care services that are in accordance with 
the latest provincial or national guidelines and standard of care. 
Cognitive behavioral therapy was identified as the most effective non-
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pharmacological intervention for the treatment of depression in PL WHA, and was shown to 
improve HAART adherence (Safren et al. , 2009; Safren et al. , 2012; Sherr et al. , 2011). In 
many communities access to trained counselors can be a barrier to implementing this 
intervention. NPs have the option to address this barrier by offering CBT to their clients. 
There is no restriction, in terms of scope of practice, placed on NPs who wish to offer CBT 
(CRNBC, 2013). In BC, the Cognitive Behavioral Interpersonal Skills (CBIS) manual and 
associated training sessions are a joint initiative between the BC Ministry of Health and the 
BC Medical Association and are available to primary care providers who wish to increase 
their competency in CBT techniques (CBIS Manual, 2009). As well, there are numerous 
other CBT training courses directed at primary care providers such as those offered by the 
Center for Addiction and Mental Health or CBT Canada. By offering in-office CBT to their 
clients, NPs have the opportunity to improve access to a highly effective non-pharmacologic 
treatment option for co-morbid depression. 
Nicotine dependence is associated with both increased risk of depression and 
HAART non-adherence (Richardson et al. , 2009; Tedaldi et al. , 2012; Webb et al., 2009). 
Smoking cessation counseling is an important health promotion activity that all health care 
providers, including NPs, should provide to clients. This is particularly important for HIV-
positive individuals because they are at increased risk for cardiovascular disease and 
smoking can compound the risk of developing heart disease by up to four times (BC-CfE, 
2011; Health Canada, 2012b). Additionally, long-term HAART therapy is associated with 
increased risk of developing insulin resistance, diabetes mellitus, renal disease and 
osteoporosis, and these conditions may be exacerbated by nicotine use (Canadian Diabetes 
Association, 2013; Ejerblad et al. , 2004; Papaioannou et al., 201 0). NPs can use resources 
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such as BC Smoking Cessation Program or QuitNowCa for more information about funding 
for nicotine replacement therapy and specific tactics to use during smoking cessation 
counseling (Province of British Columbia, 2012; QuitNowCa, 2013). 
The incredible complexity of many PL WHA and the need for comprehensive primary 
health care informed by an awareness of the social determinants of health is manifested in 
the discussion on substance abuse. Injection drug use is on of the most common HIV 
exposure categories for both Aboriginal and non-Aboriginal women (PHAC, 2012b ). 
Injection drug use is identified as a risk factor for both HAART non-adherence and 
depression among HIV-positive individuals (Eiboff, Somers & Moniruzzman, 2012; Nolan et 
al. , 2011; Richardson et al., 2012). As well, alcohol use was identified as a risk factor for 
depression among Aboriginal HIV-positive individuals (Cain et al. , 2012). The root cause of 
substance abuse was not identified in this literature review; rather the intricate interactions 
between social conditions, individual actions, vulnerability to HIV, depression and HAART 
adherence were highlighted. For example, Cain et al., 2012, found that Aboriginal PLWHA 
identified drug or alcohol abuse, racism, stigmatization, childhood abuse, homelessness, 
poverty and unemployment as factors that contributed to the development of depression, and 
that depression was the driving force behind behaviors that caused them to contract HIV. 
This finding from Cain et al. (2012) demonstrates that interventions aimed at addressing a 
single issue, for example, prescribing an SSRI to treat depressive symptoms and improve 
HAART adherence, will not fully address underlying causes of this individual's poor health 
status. Additionally, the range of factors that contribute to vulnerability to HIV, depression 
and HAAR T non-adherence, are too numerous and complex for a single, primary provider to 
address without collaboration with other healthcare providers and community stakeholders. 
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Collaboration, consultation and referral. NPs are relatively new primary care 
providers in the British Columbian health care sector. This newness may represent a 
tremendous opportunity for NPs to create a unique space within the health care system by 
promoting their expertise in providing collaborative primary care services, embedded in 
primary health care principles, that recognize and address the impact that the social 
determinants have on the health of their clients. HN is a complex disease that requires both 
biomedical interventions such as pharmacological treatment, as well as, social interventions 
aimed at reversing the social inequities that predispose individuals to contracting this disease 
and experiencing poorer outcomes. A single care provider cannot provide the range of 
services required in the treatment and management of marginalized PL WHA, and attend to 
ameliorating the social determinants of health. Therefore, collaboration with other healthcare 
providers and community partners is required for comprehensive HIV prevention and care. 
Collaborative practice is a process of"communications and decision making that 
enables the separate and shared knowledge and skills of care providers to synergistically 
influence the client/patient care provided (Canadian Nurse Practitioner Initiative [CNPI], 
2006, p.21). Quinlan and Robertson (2013) suggest that NPs are skilled at sharing knowledge 
within collaborative teams because NP education spans the gap between medical, nursing 
and other allied health disciplines. This literature search found that comorbid depression and, 
in some instances, HAART adherence were improved with clients cared for within 
collaborative, multidisciplinary models of care (Adams et al., 20 12; Coleman et al., 20 12; 
Pyne et al., 2011). The applicability of these models to primary care practice is limited 
because these models were based on highly specialized mental health teams dedicated to the 
care ofHIV-positive clients with comorbid depression. However, aspects ofthese 
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collaborative care models may have potential to be integrated into primary care collaborative 
practice. For example, Pence et al. (2012) recommend training clinic staff, such as, registered 
nurses, social workers, counselors or pharmacists to share the responsibility for the 
administration and scoring of depression-rating tools, and for screening for adverse side-
effects related to antidepressant use. 
The intent of collaborative practice is to increase the options available to clients for 
accessing primary care services. The unique feature of collaborative practice is that clients 
are able to directly access the type of services they need, when and where they need to 
(CNPI, 2006). For example, a client who is cared for within multidisciplinary, collaborative 
practice has the option to make an appointment directly with a mental health clinician 
because they have been having trouble since their recent HIV diagnosis. The mental health 
clinician may be able to use their knowledge and skills to manage this issue independently, 
or they may need to consult with another primary care provider, such as NP, to discuss the 
possibility of initiating medication to help manage this client's issues. 
As stipulated in CRNBC's Scope of Practice for Nurse Practitioners: Standards, 
Limits and Conditions document, the NP must ensure at least yearly consultation with an 
HIV-specialist physician to review response to HAART (2013). Collaboration with an HIV 
specialist pharmacist is recommended to reduce the risk of adverse drug events. This 
relationship is particularly important when the NP considers initiating antidepressant therapy 
because of the potential for drug-drug interactions of medications that share the CYP450 
pathways. Additionally, the NP may need to collaborate with physicians for clients who 
require prescriptions that fall outside the NP's prescribing authority, such as methadone or 
opioids. For the management of comorbid depression, NPs may need to consult with a 
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psychiatrist for the diagnosis, treatment and management of clients with severe depression 
that are not responding to treatment, or other comorbid mental illnesses such as bipolar 
disorder or schizophrenia. A consideration specific to the care women, is childbearing 
potential. The risk of transmitting HIV from mother to child can be drastically reduced with 
appropriate HAART. However, due to concerns about teratogenicity of some HAART 
medications, the NP should refer all female clients, who are or considering becoming 
pregnant to an HIV specialist at a women's health clinic, such as the Oak Tree Clinic in 
Vancouver, BC. 
A collaborative practice approach is not confined for use with other healthcare 
professionals. An NP can use a collaborative approach with community partners such as 
ASOs, schools, cultural or special interest groups. Collaboration with community partners is 
important because it provides NPs with the opportunity to discover what and how services 
are being delivered, as well as, highlighting areas of service gaps or needs, that may direct 
future research or program development and avoid duplication of services. For example, in 
Prince George, it was identified that a potential barrier to women reporting sexual assaults 
was that the only way for the sexual assault examination to be completed was to present to 
the local emergency department for care. A partnership between the needle exchange 
program, other sister organizations and a specially trained NP was established to initiate a 
pilot project where the NP would be available to complete sexual assault examinations when 
and at whichever community partner that women presented to (T. Day, personal 
communication, October 8, 2013). In another example from Prince George, representatives 
from AIDS Services Organizations (ASOs), the needle exchange program and HIV clinicians 
meet on a monthly basis to discuss the clinical care ofHIV positive clients who may be 
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struggling with treatment issues. At these meetings strategies are devised and implemented 
with the input of team members to support that client to achieve optimal treatment outcomes 
(Tu et al., 2013). 
Engaging in relevant research activities. The NP is expected to seek out 
opportunities to conduct or participate in research and to initiate the development and 
implementation of practice guidelines and standards of care (CRNBC, 2013). NP research 
should "be planned and patient-centric, and must demonstrate the contribution of the NP role 
to the team, defined by outcomes of care at the patient, organizational and healthcare system 
levels (Pogue, 2007, p.36)". NP participation in research will help to ensure that practice 
guidelines are relevant to NP practice, as well as to promote the NP perspective and 
contribution to health care. The NP is also expected to take a leadership role in adopting and 
disseminating new research findings or best practice guidelines (CRNBC, 2013). 
Considerations for future research. A significant finding from this research project 
is the lack of research conducted with depressed female and/or Aboriginal participants, as 
well as research examining the role of the NP in the delivery ofHIV care, despite NPs 
having the authority to collaboratively manage the care ofPLWHA. The dearth of research 
with female participants is significant because HIV-positive women may posses uniquely 
female factors such as childbearing potential, family care-giving responsibilities, and 
metabolic differences that may be overlooked or devalued, leading to further 
marginalization. Likewise, cultural practices and the legacy of colonialism and residential 
school may create factors unique to Aboriginal people that impact HIV vulnerability and 
treatment outcomes in ways that are yet to be uncovered by researchers (Pearce et al., 2008). 
This paper also identified several social determinants of health, such as, poverty, food 
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insecurity, homelessness and gender discrimination that are associated with both depression 
and HAART non-adherence; however, little evidence was found to recommend specific 
interventions to address these factors. Reutter and Kushner (20 1 0) advocate for nursing 
participation in research that seeks to uncover the causal pathways between social inequity 
and poor health. This research will allow for the development of interventions to that will 
directly address the mechanisms by which social inequities threaten health status. They 
further suggest, that because many health inequities stem from public policy, nurses should 
engage in research that investigates the link between public policy and social inequity 
(Reutter & Kushner, 2010). 
There is tremendous need for NPs who wish to initiate or address some of the gaps 
identified by this project. In an effort to increase the amount of research conducted with 
female participants, NPs can discuss, with their female or Aboriginal clients, the potential 
risks and benefits of participation in clinical trials or research projects. For example, the NP 
could provide information on the Canadian HIV Women's Sexual and Reproductive Health 
Cohort Study that is currently enrolling female participants to examine factors that influence 
HIV-positive women's access to health care services (Canadian HIV Women's Sexual and 
Reproductive Health Cohort Study [CHIWOS], 2013). 
As well, NPs can network with other NPs working with HIV -positive clients to 
discuss and learn about challenges and practice issues other NPs are struggling with and 
develop research proposals accordingly. In this way, research studies will reflect not only the 
issues affecting NPs, but will also be applicable to the clients and populations NPs are 
currently working with. These research findings can also guide the continued integration of 
the NP role and to facilitate the transformation of health care delivery models that are 
inclusive ofNP practice. 
Assess and Diagnose Client's Health Status 
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By utilizing the current, evidence-based practice guidelines and applying education 
and skills, the NP can provide care across the lifespan ofHIV-positive women. By fostering 
an open and trusting relationship NPs can "work collaboratively with the clients to identify 
and mitigate health risks, promote understanding of health issues and support health 
behavior" (CRNBC, 2010, p. 12). The NP must be willing to take part in conversations about 
potentially sensitive topics; such as, sexual practices, drug or alcohol use, living 
arrangements or financial situation, so as to develop a complete, holistic picture of the 
client's health status. Factors associated with HAART non-adherence and depression, such 
as coping style, stigmatization, annual income less than $15 000, or appearance concerns 
related to lipodystrophy may not be revealed by clients, without a respectful inquiry on 
behalf of the primary care provider (Bianco et al., 2011; Logie et al., 2013; O'Neil et al., 
2011; Palmer et al., 2011 ). This highlights the value ofNPs' foundation in nursing, because 
nurses have a history of, and are comfortable and well versed in approaching health from a 
holistic perspective (CNPI, 2006; Quinlan & Robertson, 2013; Reutter & Kushner, 2010). 
In my experience, both as a registered nurse and student NP, it can be challenging to 
balance the requirements of biomedical clinical practice guidelines while striving to identify 
and address the social factors that may be adversely affecting the health of my client. For 
example, my priorities for an appointment may be to review recent laboratory results, 
reassess severity of depression using the PHQ-9, and if necessary adjust the antidepressant 
dosage. However, the priority for the client may that they need a form completed so they 
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could obtain safer housing, or they may need assistance obtaining food, or simply need 
support because they are in emotional crisis. As an NP student it was overwhelming trying to 
address everything in each visit, however, from observing the practice of experienced NPs, it 
has become evident that NPs have the ability to simultaneously address the client's current 
concerns, while diligently attending to the priorities of evidence-based care. NP education 
and practice are based on primary health care principles and an awareness of the social 
determinants of health. So, for example, as part of routine care, an NP is able to interpret the 
biological markers of HIV disease status, as well as, inquire about social issues such as 
unstable housing, food insecurity and poverty that contribute the client's overall health 
status. 
Therapeutic Management of Client's Health Care 
Two important findings from this project are that CBT and antidepressants were 
shown to both effectively treat depression and improve HAART adherence amongst 
depressed PL WHA, and that there were very few studies that specifically examined the 
treatment of depression and HAART adherence among female PLWHA. This not only 
highlights a potential area for research, it also calls for clinicians to be cautious when they 
apply existing research to clinical practice. In particular, the scarcity of pharmaceutical trials 
involving female participants may mean that clinicians are unaware of important 
pharmacokinetic or pharmacodynamic factors unique to female clients (Montforte et al., 
2010). For example, the nRTI, emtricitabine, is more commonly associated with adverse 
gastrointestinal dermatological side effects in women (BC-CfE, 2013, February). Another 
example is when working with women of child-bearing age, it is important to be mindful of 
medications contraindicated during pregnancy, such as, the NNRTI, efavirenz, due to 
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concerns of teratogenicity (BC-CfE, 2013, February). 
NPs are skilled at counseling clients on the risks and benefits of both non-
pharmacologic and pharmacologic treatment options. The NP ensures that the information 
presented to the client is current, evidence informed, and is at a level appropriate to the 
client's level of literacy and understanding. For example, while the NP does not initiate 
HAAR T medications, the role of the NP is to counsel the client on the general risks and 
benefits of treatment versus no treatment, to outline what treatment may entail, to answer any 
questions that the client may have, and to offer support regardless of the client's decision of 
whether or not to initiate HAART. When counseling clients, it is important for NPs to be 
mindful that for many marginalized women, HIV is "just one of many competing problems" 
(McCall, Browne, Reimer-Kirkham, 2009, p. 1776). This means that the decision of an HIV-
positive woman to enter into HAART may not be the most important decision that she has to 
make at that time because she has several other more pressing issues to address. For 
example, she may be struggling in an abusive relationship, caring for children or battling 
substance abuse. A fear ofbeingjudged for their decisions and life circumstances is cited as 
a reason why some HIV-positive women avoid seeking medical treatment (McCall et al., 
2009). As primary care providers, their clients may view NPs as being in a position of power, 
and there is potential for further marginalization ifNPs do not demonstrate that they respect 
and value their client's decisions regarding treatment and lifestyle. 
Successful treatment and management ofHIV-positive clients relies heavily on 
pharmacotherapy. In order to provide comprehensive HIV care, NPs must resist the 
temptation to focus solely on the biomedical aspects of HIV care and, as stated above, make 
a conscious effort to engage in activities to address the social determinants of health. Browne 
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et al. (2012) suggest that comprehensive primary health care requires that clinicians work "to 
address these [social determinants of health] issues as legitimate and routine aspects of care, 
often as the main priority" (p. 11 ). In practical terms, this means that in addition to inquiring 
about their client's social circumstances, the NP must be willing to assist their clients in 
activities aimed at achieving improved social determinants ofhealth, such as assisting 
applying for income assistance, accessing safe housing, enrolling in drug treatment programs 
or acquiring paid employment (Browne et al., 2012). A potential barrier to addressing the 
social determinants of health is that changing the social conditions in which people live is 
often a slow process that may take several years or generations to accomplish, and outcomes 
may be difficult to demonstrate or articulate to the people in charge of providing funding to 
HIV-care programs on a year-to-year basis. This highlights the importance ofNP 
participation in research, policy development and health program planning that includes 
outcome measures that reflect the benefits of care and services that NPs provide. For 
example, modifiable social determinants of health such as obtaining stable housing or food 
security can be incorporated into models of care for PL WHA as target outcomes that are as 
important to achieve as viral suppression and HAAR T adherence. 
As the primary care provider, the NP is responsible for coordinating their client's 
health care plan. This includes ensuring that all consultations with HN or mental health 
specialists, diagnostic testing and referrals to other specialists or programs are completed 
within a timely manner. The NP also ensures that any recommendations made by specialists, 
or other health care team members, are incorporated into the client's care plan. Another 
important aspect ofthe NP role in the care ofHIV-positive women is to ensure that all the 
other age or population specific screening and interventions such as immunizations, and 
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screening for cervical cancer, renal or cardiovascular disease, diabetes mellitus or 
osteoporosis are up to date according to current guidelines (BC-CfE, 2011 ). This is important 
because HIV-positive women, who are optimally treated with HAART, are living longer and 
as a consequence of both increased longevity and some HAART side-effects are developing 
non-HIV related chronic conditions such as heart disease, diabetes, osteoporosis and cancer 
(BC-CfE, 2011). Finally, as the primary care provider, the NP is responsible for addressing 
any acute conditions, which fall within the NP scope of practice that may be unrelated to 
HIV care. 
Promoting Health and Preventing Illness/Injury 
The final competency to be discussed is promoting health and preventing injury. To 
fulfill this competency NPs are expected to utilize a primary health care approach, and their 
knowledge of the social determinants ofhealth to advocate for clients and their health care 
needs (CRNBC, 2013). NPs are also expected to provide care beyond the individual level, 
and implement interventions focused on improving the health of families, communities and 
entire populations. While activities associated with a high risk of HIV transmission, such as 
unsafe injection drug use or unprotected sexual intercourse, occur at the individual level, 
social factors, such as poverty, lack of education, or gender, create conditions that facilitate 
high-risk behaviors (Krusi, Wood, Montaner & Kerr, 2010). In the absence of a definitive 
cure for HIV, the only strategy to stop the spread of this disease is to prevent transmission. 
As part of routine care NPs can offer HIV screening to all sexually active adults at least 
yearly, after a potential HIV exposure, upon client request, or as part of routine prenatal care. 
In addition, NPs can counsel individuals on strategies to reduce HIV transmission risk such 
as safer sex and drug use habits. 
72 
Diligent screening for cervical cancer is important because HIV -positive women are 
ten-times more likely to have an abnormal papanicolaou than non-HIV positive women (BC-
CfE, 2011). This many require more frequent screening than what is currently recommended 
in the cervical cancer screening guidelines for women. As well, the incidence of HPV is 
higher among HIV -positive women, and particularly those with low CD4+ counts (BC-CfE, 
2011). The recommendation for the use of the human papilloma virus vaccine in HIV-
positive women is unclear because, currently there are very few studies that have evaluated 
with safety, efficacy and immunogenicity ofthis vaccine among HIV-positive women. 
Again, this highlights the need for research specifically addressing the care ofHIV-positive 
women. 
At the population level, NPs can collaborate with community stakeholders such as 
public health agencies, ASOs, schools, or cultural societies to develop HIV awareness 
campaigns, programs to increase HIV screening, or initiatives to increase safe housing or 
meal programs to increase access to secure food sources. As well, NPs are required to 
advocate on behalf of their clients. This may take the form of lobbying local, provincial or 
federal policy makers to support increasing minimum wages, the creation of programs to 
increase food security for families, or to expand the capacity of drug treatment programs. 
Nurse practitioners possess the educational background and legislated scope of 
practice to care for marginalized, HIV -positive women, with comorbid depression. The role 
of the NP in the care of this population includes traditional biomedical activities such as 
ordering and interpreting tests, prescribing medications and completing physical assessments 
and history taking. NPs also engage in activities such as collaboration with other health care 
providers or community partners, or lobbying policy makers to address the social 
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determinants of health that may be adversely affecting the health of their clients. NPs have 
the potential to play an important role in primary prevention strategies to prevent the 
transmission of HIV, and secondary prevention strategies to increase HIV screening rates in 
all sexually active individuals. The NP role calls for participation in research that furthers 
knowledge development in the field of HIV care, as well as NP practice. 
Limitations 
The biggest challenge that emerged from this study is the lack of research involving 
female participants and NPs. This meant that the recommendations for practice are based on 
findings from research conducted with predominantly HIV -positive males. As such, some of 
the nuances unique to the care of HIV -positive women with comorbid depression might have 
been inadvertently overlooked by this literature review. Similarly, the scope of this study was 
too broad. In hindsight a more manageable approach to this project would have been to focus 
on a single aspect of marginalization, for example, homelessness or food insecurity. In the 
next section, specific recommendations for NPs working with marginalized HIV positive 
women with comorbid depression are outlined. 
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CHAPTER FIVE 
Recommendations for Practice 
In the preceding chapter, the role of the NP caring for marginalized HIV-positive 
women with comorbid depression was discussed in terms of the four key competencies 
required ofNP practice in BC: (a) professional role, responsibility and accountability, (b) 
assess and diagnose client's health status, (c) therapeutic management of client's health care, 
and (d) promoting health and preventing illness/injury. Based on the research articles 
reviewed, specific recommendations for NPs wanting to optimize HAAR T adherence among 
marginalized, HIV -positive women will be outlined in this section. These recommendations 
will be organized according to the key competencies required in NP practice discussed in the 
preceding chapter and presented in Table 3. 
Table 3 
Competencies Required of and Practice Recommendations for British Columbian Nurse 
Practitioners Seeking to Optimize Adherence to Highly Active Antiretroviral Therapy Among 
Marginalized HIV-Positive Women with Comorbid Depression 
Competency Required of Nurse Practice Recommendation Specific to the Care of 
Practitioners in British Marginalized HIV-Positive Women with Comorbid 
Columbia Depression 
Establish & maintain • Attend a BC-CfE HIV preceptorship program such as 
professional role, responsibility the John Ruedy Immunodeficiency Clinic 
& accountability Preceptorship Program for Nurse Practitioners 
• Utilize current clinical practice guidelines such as: 
o Primary Care Guidelines for the Management of 
HIV/AIDS in British Columbia (BC-CfE, 2011) 
o Therapeutic Guidelines: Antiretroviral (ARV) 
Treatment of Adult HIV Infection (BC-CfE, 
2013, February) 
o Depression and Mania in Patients with 
HIV I AIDS (NY State Department of Health 
AIDS Institute [NYHAI], 2010) 
o Evidence-based Clinical Practice Guidelines for 
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Managing Depression in Persons Living with 
HIV/AIDS (Relfet al., 2013) 
• Cognitive Behavioral Therapy training: 
o Cognitive Behavioral Interpersonal Skills 
manual and training courses (CBIS, 2009) 
• Smoking Cessation Counseling & Treatment 
o QuitNowCa 
• Seek out opportunities to participate in or conduct 
research in the field ofHIV care for women and/or NP 
practice 
• Engage in collaborative activities with health care 
team members and community partners aimed at 
addressing inequities in the social determinants 
affecting the health of clients 
Assess and diagnose client's • Use the 'Two Quick Questions' or Patient Health 
health/illness status Questionnaire 2 (PHQ-2) to screen for depression at 
least annually or when depressive symptoms are 
present (NYHAI, 2010) 
• Use a clinically validated tool to diagnose and monitor 
response to depression treatment. Appropriate 
depression screening tools include: 
o Patient Health Questionnaire (PHQ-9) 
o Center for Epidemiologic Study Depression 
(CES-D) Rating Scale 
o Beck Depression Inventory (BDI) 
o Hamilton Rating Scale for Depression (HAM-
D/HDI) 
• Monitor for HAAR T adherence, adverse side effects, 
and potential medication interactions on each visit 
(BC-CfE, 2011) 
• Ensure HIV related history and physical examination, 
including assessment of social determinants of health, 
are completed as per current guidelines (BC-CfE, 
2011) 
• Ensure all age appropriate and HIV /HAAR T related 
screening and blood work is completed according to 
current guidelines (BC-CfE, 2011) 
Therapeutically manage client • Foster a collaborative environment both with clients 
health care and other health care team members 
• Engage in activities aimed at addressing social 
inequities as part of routine practice (Browne et al., 
2012) 
• Refer clients to AIDS Service Organizations &/or 
Medication Adherence Support Program 
Therapeutically manage client 
health care 
• Provide information about the pharmacological and 
non-pharmacological options for the treatment of 
depression 
o Non-pharmacological: 
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• First Line: Cognitive Behavioral Therapy 
(Safren et al., 2009) 
• Alternatives: Mindfulness-based stress 
reduction, yoga, meditation, breathing 
exercises and moderate intensity aerobic 
exercises (Relf et al., 2013; Lyerly et al., 
2009) 
o Pharmacological: 
• First Line 
• Selective Serotonin Reuptake 
Inhibitors: Citalopram or Escitalopram 
• Second Line 
• Serotonin-Norepinephrine Reuptake 
Inhibitor: Venlafaxine 
• Novel Action Antidepressant: 
Bupropion (Freudenrich et al., 201 0; 
NYHAI, 2010) 
• Follow current BC-CfE guidelines & CRNBC Practice 
Standards for the renewal of HAAR T medications 
(BC-CfE, 2011; BC-CfE, 2013, February; CRNBC, 
2013) 
• Consultation and collaboration: 
o HIV -specialist physician upon diagnosis with 
HIV and at least yearly, or when diagnosed with 
opportunistic infections or evidence of treatment 
failure/intolerance (BC-CfE, 2011; CRNBC, 
2013) 
o Oak Tree Clinic for care of women who are 
pregnant, considering pregnancy or inquiries 
regarding the care of HIV positive women and 
their family Telephone Line 1 888 711 3030 
o HIV -specialist pharmacist when initiating or 
adjusting medication regimens 
o Rapid Expert Advice and Consultation in HIV 
(REACH) Telephone Line 1 800 665 7677 
o Psychiatrist and/or mental health clinician in the 
diagnosis of depression the is not responding to 
treatment, or in the presence of other comorbid 
mental illnesses such as bipolar or schizophrenia 
(NYHAI, 2010) 
o Community partners to engage in advocacy, 
awareness or community development activities 
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Promote health and prevent 
illness/injury 
• Offer routine, annual HIV screening to all sexually 
active adults, or when a client reports a potential 
exposure or upon client request (HIV Testing Initiative 
in Family Practice, nd) 
• Offer HIV transmission, prevention and treatment 
counseling as part of routine care for all clients 
• Participate in the development of policies that promote 
and protect the social determinants of health for 
marginalized, HIV -positive women 
• Participate in community or health orientated activities 
aimed at raising HIV awareness 
Conclusion 
HIV -positive women with comorbid depression are a concern for HIV clinicians 
because depression is associated with suboptimal adherence to HAART and poor disease 
outcomes such as inability to achieve viral suppression and a more rapid progression to 
AIDS. As well, suboptimal adherence is associated with increased risk of the development 
and transmission ofHAART resistant strains ofHIV. HIV-positive women are more likely to 
experience depression than men. Social factors such as poverty, homelessness, food 
insecurity, PTSD, stigma, gender or racial discrimination and injection drug use are 
associated both increased ofHAART non-adherence and depression. This project found 
significant evidence that demonstrated HIV -positive individuals respond as well to 
depression treatment as non-HIV positive individuals, and that the treatment of depression is 
associated with both improved HAART adherence and improved quality oflife and disease 
outcomes. Effective treatments for comorbid depression in HIV-positive people include 
cognitive behavioral therapy, and pharmacological intervention with SSRis. However, 
several gaps were identified in the research reviewed for this project. First there was a 
scarcity of research conducted with female participants. This is of importance for HIV 
clinicians because females respond to some HAAR T medications and are affected by social 
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factors differently. The second gap in the research was that no studies evaluated strategies to 
address social inequities. The third gap was on the topic ofNP practice with HIV-positive 
individuals. 
The role of the NP caring for marginalized, HIV -positive women with comorbid 
depression was inferred by carefully extrapolating the findings of the literature search based 
on the competencies required ofNP practicing in BC. NPs have the educational background, 
legislated scope of practice and competency framework that allows them to provide 
comprehensive and collaborative care. NPs possess the knowledge and skills to attend to the 
biomedical needs, such as renewing HAART prescriptions, completing comprehensive 
examinations, and ordering and interpreting diagnostic tests. NP education is steeped in an 
awareness of the social determinants ofhealth, as well as theory on community development, 
program planning and social justice that allows NPs to put their awareness into action. A 
unique characteristic of the care that NPs can provide is their potential to foster collaborative 
relationships with healthcare team members, sister organizations and community 
stakeholders. This is important because care ofHIV-positive individuals is tremendously 
complex and requires expertise from a wide range of both healthcare and non-healthcare 
related disciplines. As well, addressing the social inequities that are negatively impacting the 
health of PL WHA requires not only the efforts ofNPs, but also participation from clients, 
community stakeholders and policy makers. NPs can take a leadership role in fostering 
collaborative environments in which to enact social change to better the living conditions of 
marginalized individuals. 
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